Substances that are recognized by the immune system and induce an immune reaction.
Substances elaborated by bacteria that have antigenic activity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Substances elaborated by viruses that have antigenic activity.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Substances of fungal origin that have antigenic activity.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.
The major group of transplantation antigens in the mouse.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.
Neoplasms containing cyst-like formations or producing mucin or serum.
Antibodies produced by a single clone of cells.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
Tumors or cancer of the SKIN.
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
Sites on an antigen that interact with specific antibodies.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Tumors or cancers of the KIDNEY.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the LUNG.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
Tumors or cancer of the THYROID GLAND.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the LIVER.
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.
Established cell cultures that have the potential to propagate indefinitely.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A general term for various neoplastic diseases of the lymphoid tissue.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Tumors or cancer of the PAROTID GLAND.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the COLON.
Tumors or cancer of the ENDOCRINE GLANDS.
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Tumors or cancer of the EYE.
An encapsulated lymphatic organ through which venous blood filters.
Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the NOSE.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Tumors or cancer of the SALIVARY GLANDS.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
A benign epithelial tumor with a glandular organization.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Tumors or cancer of the PROSTATE.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Tumors or cancer of the UTERUS.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Tumors or cancer of the INTESTINES.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Tumors or cancer of the THYMUS GLAND.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Tumors or cancer located in bone tissue or specific BONES.
The sum of the weight of all the atoms in a molecule.
A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.
A malignant epithelial tumor with a glandular organization.
A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.
A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.
A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Elements of limited time intervals, contributing to particular results or situations.
Tumors or cancer of the SPLEEN.
Tumors or cancer of the BILE DUCTS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Neoplasms composed of more than one type of neoplastic tissue.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Tumors or cancer of the MANDIBLE.
Proteins prepared by recombinant DNA technology.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Cancer or tumors of the MAXILLA or upper jaw.
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Tumors or cancer of the STOMACH.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
Diagnostic procedures involving immunoglobulin reactions.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
A group of dominantly and independently inherited antigens associated with the ABO blood factors. They are glycolipids present in plasma and secretions that may adhere to the erythrocytes. The phenotype Le(b) is the result of the interaction of the Le gene Le(a) with the genes for the ABO blood groups.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Tumors or cancer of the anal gland.
Tumors or cancer of the human BREAST.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Immunoglobulins produced in a response to HELMINTH ANTIGENS.
Tumors or cancer of the URINARY BLADDER.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Antigens which may directly stimulate B lymphocytes without the cooperation of T lymphocytes.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
Tumors or cancer of the MOUTH.
Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.

Glycopeptides from the surgace of human neuroblastoma cells. (1/9302)

Glycopeptides suggesting a complex oligosaccharide composition are present on the surface of cells from human neuroblastoma tumors and several cell lines derived from the tumors. The glycopeptides, labeled with radioactive L-fucose, were removed from the cell surface with trypsin, digested with Pronase, and examined by chromatography on Sephadex G-50. Human skin fibroblasts, brain cells, and a fibroblast line derived from neuroblastoma tumor tissue show less complex glycopeptides. Although some differences exist between the cell lines and the primary tumor cells, the similarities between these human tumors and animal tumors examined previously are striking.  (+info)

Immune responses to all ErbB family receptors detectable in serum of cancer patients. (2/9302)

Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors.  (+info)

The role of alternative splicing of the adhesion molecule, CD44, in lymphoid malignancy. (3/9302)

AIM: To investigate the expression of CD44 isoforms containing variant exon 6 (v6) in a well characterised cohort of patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), and to correlate this with phenotype and disease course. METHODS: Cryostat sections of OCT embedded diagnostic nodal material from NHL patients and cryopreserved mononuclear preparations from CLL patients were used as sources of RNA. After reverse transcription, PCR was carried out with amplimers positioned at either side of the variant exon insertion site to amplify all possible CD44 isoforms. Those isoforms containing v6 were identified after Southern blotting and hybridisation with a radiolabelled oligonucleotide. RESULTS: Of 32 NHL samples analysed, 16 did not express CD44 isoforms containing v6, six expressed an isoform containing exon v6 alone, and 10 expressed v6 long isoforms which contained exon v6 in addition to other variant exons. These data did not correlate with lymphoma classification, disease staging, or the presence or absence of extranodal disease. However, those patients expressing v6 long CD44 isoforms had a worse overall survival than those that did not. The plateau of the survival curves was 50% compared with 82%. No v6 long isoforms were detected in the 21 CLL samples investigated. CONCLUSIONS: The expression of v6 long CD44 isoforms is associated with aggressive disease in NHL, independent of grade, stage, or presence of extranodal disease.  (+info)

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. (4/9302)

Transforming growth factor beta (TGF beta) family members are secreted in inactive complexes with a latency-associated peptide (LAP), a protein derived from the N-terminal region of the TGF beta gene product. Extracellular activation of these complexes is a critical but incompletely understood step in regulation of TGF beta function in vivo. We show that TGF beta 1 LAP is a ligand for the integrin alpha v beta 6 and that alpha v beta 6-expressing cells induce spatially restricted activation of TGF beta 1. This finding explains why mice lacking this integrin develop exaggerated inflammation and, as we show, are protected from pulmonary fibrosis. These data identify a novel mechanism for locally regulating TGF beta 1 function in vivo by regulating expression of the alpha v beta 6 integrin.  (+info)

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. (5/9302)

Interleukin (IL)-10 is a potent immunosuppressive cytokine that has been found to be present at the tumor site in a wide variety of human cancers, including transitional cell carcinoma of the bladder. Using a murine bladder tumor (MB49), which we show to express the male transplantation antigen (HY), we tested the hypothesis that IL-10 at the tumor site can block the generation of a tumor-specific type 1 immune response. We show that, despite its expression of HY, MB49 fails to prime for an HY-specific type 1 (IFN-gamma) response in normal female mice. Although MB49 does not constitutively produce IL-10, our data support a model whereby MB49 induces infiltrating cells to produce IL-10. This feature rendered the IL-10 knockout (KO) mouse, whose infiltrating cells are incapable of IL-10 production, a suitable model in which to study MB49 in the absence of IL-10. When injected into IL-10 KO mice, MB49 does prime for an HY-specific, type 1 immune response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors as compared with normal mice. We also tested the ability of tumor-induced IL-10 to inhibit immunization to a non-tumor antigen present at the tumor site. When vaccinia virus encoding beta-galactosidase (beta-gal) is injected into the tumors of normal mice, no beta-gal-specific IFN-gamma response is mounted. However, when this same viral construct is injected into the tumors of IL-10 KO mice, it produces a strong beta-gal-specific, IFN-gamma response. These studies demonstrate that tumor-induced IL-10 can block the generation of a tumor-specific type 1 immune response as well as subvert attempts to elicit a type 1 immune response to a non-tumor antigen at the tumor site.  (+info)

Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. (6/9302)

Dendritic cells (DC) are critically involved in the initiation of primary immune processes, including tumor rejection. In our study, we investigated the effect of interleukin-10 (IL-10)-treated human DC on the properties of CD8(+) T cells that are known to be essential for the destruction of tumor cells. We show that IL-10-pretreatment of DC not only reduces their allostimulatory capacity, but also induces a state of alloantigen-specific anergy in both primed and naive (CD45RA+) CD8(+) T cells. To investigate the influence of IL-10-treated DC on melanoma-associated antigen-specific T cells, we generated a tyrosinase-specific CD8(+) T-cell line by several rounds of stimulation with the specific antigen. After coculture with IL-10-treated DC, restimulation of the T-cell line with untreated, antigen-pulsed DC demonstrated peptide-specific anergy in the tyrosinase-specific T cells. Addition of IL-2 to the anergic T cells reversed the state of both alloantigen- or peptide-specific anergy. In contrast to optimally stimulated CD8(+) T cells, anergic tyrosinase-specific CD8(+) T cells, after coculture with peptide-pulsed IL-10-treated DC, failed to lyse an HLA-A2-positive and tyrosinase-expressing melanoma cell line. Thus, our data demonstrate that IL-10-treated DC induce an antigen-specific anergy in cytotoxic CD8(+) T cells, a process that might be a mechanism of tumors to inhibit immune surveillance by converting DC into tolerogenic antigen-presenting cells.  (+info)

Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. (7/9302)

BACKGROUND: Proper treatment of lymph node-negative breast cancer depends on an accurate prognosis. To improve prognostic models for this disease, we evaluated whether an immunohistochemical marker for proliferating cells, Ki-S2 (a monoclonal antibody that binds to a 100-kd nuclear protein expressed in S, G2, and M phases of the cell cycle), is an accurate indicator of prognosis. METHODS: We studied 371 Swedish women with lymph node-negative breast cancer; the median follow-up time was 95 months. The fraction of tumor cells in S phase was assessed by flow cytometry, and tumor cell proliferation was measured immunohistochemically with the monoclonal antibodies Ki-S2 and Ki-S5 (directed against the nuclear antigen Ki-67). A combined prognostic index was calculated on the basis of the S-phase fraction, progesterone receptor content, and tumor size. RESULTS: In multivariate analyses that did or did not (263 and 332 observations, respectively) include the S-phase fraction and the combined prognostic index, the Ki-S2 labeling index (percentage of antibody-stained tumor cell nuclei) emerged as the most statistically significant predictor of overall survival, disease-specific survival, and disease-free survival (all two-sided P<.0001). In the risk group defined by a Ki-S2 labeling index of 10% or less, life expectancy was not statistically significantly different from that of age-matched women without breast cancer, whereas the group with a high Ki-S2 labeling index had an increased risk of mortality of up to 20-fold. CONCLUSIONS: Cellular proliferation is a major determinant of the biologic behavior of breast cancer. Prognosis is apparently best indicated by the percentage of cells in S through M phases of the cell cycle. Measurement of the Ki-S2 labeling index of a tumor sample may improve a clinician's ability to make an accurate prognosis and to identify patients with a low risk of recurrence who may not need adjuvant therapy.  (+info)

Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. (8/9302)

The mRNA expression of the tumor-associated antigens MAGE and GAGE was examined in 60 high-grade brain tumors. This analysis was performed by using reverse transcription-PCR, Southern blotting, and sequencing. It was demonstrated that, of the eight GAGE genes, GAGE-2 and -7 were expressed in five of seven normal brains. Four groups of tumors--adult glioblastoma multiforme (n = 20), pediatric glioblastoma multiforme (n = 9), medulloblastomas (n = 15), and ependymomas (n = 14)--were analyzed for mRNA expression. The following frequencies were observed: MAGE-1, 0, 0, 13, and 0%, respectively; MAGE-2, 5, 11, 60, and 57%; MAGE-3 & -6, 0, 0, 13, and 0%; GAGE-1, 65, 11, 13, and 43%; and GAGE-3-6 and -8: 75, 78, 47, and 93%, respectively. Two unclassified tumors expressed GAGE-3-6 and -8 only. The absence of GAGE-1 expression in normal brain, its relatively high frequency of expression in high-grade brain tumors, and its unique 3' sequence, suggest it may represent a useful target for specific immunotherapy. The detection method of reverse transcription-PCR and Southern blotting may also be useful for rapid screening of biopsy specimens both for diagnostic purposes and to determine a patient's eligibility for specific immunotherapy.  (+info)

In several human malignancies, the expression of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is associated with aggressive characteristics and poor overall survival. RCAS1 alters the tumor microenvironment by inducing peripheral lymphocyte apoptosis and angiogenesis, while reducing the vimentin-positive cell population. Although proteolytic processing, referred to as “ectodomain shedding,” is pivotal for induction of apoptosis by RCAS1, the proteases involved in RCAS1-dependent shedding remain unclear. Here we investigated proteases involved in RCAS1 shedding and the association between tumor protease expression and serum RCAS1 concentration in uterine cancer patients. A disintegrin and metalloproteinase (ADAM) 9 was shown to be involved in the ectodomain shedding of RCAS1. Given the significant correlation between tumor ADAM9 expression and serum RCAS1 concentration in both cervical and endometrial cancer as well as the role for ADAM9 in RCAS1 shedding, further
Recombinant Human Tumor-associated Calcium Signal Transducer 2/TROP-2 (C-Fc)|| Human Tumor-associated Calcium Signal Transducer 2/TROP-2 (C-Fc)|| Tumor-associated Calcium Signal Transducer 2/TROP-2 (C-Fc)
The human 5T4 oncofoetal antigen is expressed by all types of trophoblast in pregnancy but is not detected on most adult tissues, although low levels are found on some epithelia. However, this antigen is strongly expressed by many cancers and tumour-associated labelling correlates with metastatic spread and poor clinical outcome for patients with gastric and colon cancer. Over-expression of the gene influences cell adhesion, shape and motility, which may be related to changes in the cellular localisation of the 5T4 oncofoetal antigen as malignancy develops. To establish whether the 5T4 oncofoetal antigen can serve as a tumour-specific marker for oral cancer and precancer, we have evaluated the pattern of expression on biopsies of normal, inflamed and dysplastic oral mucosa using immunohistochemistry. Oral mucosa, taken from different sites in the mouth, expressed the 5T4 oncofoetal antigen with varying intensity and pattern. The majority of the immunoreactivity was detected in the basal and ...
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject areas.
The biologic and clinical significance of the oncofetal antigens carcinoembryonic antigen (CEA) and alpha1-fetoprotein (AFP) are discussed. Although the current assays for these molecules are not tumor-specific, measurement of these molecules in the circulation of cancer patients is useful either for tumor diagnosis or for management of the cancer patient in the postoperative or post-chemotherapy state. An approach to increasing the specificity of the CEA radioimmunoassay is described. ...
Haughton, G; Lanier, L L.; Babcock, G F.; Lynes, D M.; and willexploit, N., Ation of the surface idiotype as tumor specific antigen. (1978). Subject Strain Bibliography 1978. 2066 ...
Liang, W and Cohen, E P., Detection of thymus leukemia antigens on the surface membranes of murine leukemia cells resistant to thymus leukemia anti- bodies and guinea pig complement. (1977). Subject Strain Bibliography 1977. 2311 ...
As a leading supplier of innovative life science research tools, Creative Diagnostics continues to expand its products portfolio by offering of unique antigens for researchers globally, which is supported by extensive research, development, and validation for superior quality. The addition of antigen products and services will enable scientists to work on more specific projects, and also provide leading researchers and diagnostic manufacturers with a more diverse antigen selection, which facilitates the development of assays with greater specificity and sensitivity.. These newly released antigens are rigorously tested to meet the demand in research and development and are featured with excellent quality, including Viral Antigens, Bacterial Antigens, Fungal Antigens, Parasitic Antigens, Immunoglobulin, Hapten, Cardiac Biomarkers and so on. With this expanded offering of antigens products, Creative Diagnostics enables scientists to achieve more complete analysis experiments. These products along ...
Many patients develop tumor antigen-specific T cell responses detectable in peripheral blood mononuclear cells (PBMCs) following cancer vaccine. However, measurable tumor regression is observed in a limited number of patients receiving cancer vaccines. There is a need to re-evaluate systemically the immune responses induced by cancer vaccines. Here, we established animal models targeting two human cancer/testis antigens, NY-ESO-1 and MAGE-A4. Cytotoxic T lymphocyte (CTL) epitopes of these antigens were investigated by immunizing BALB/c mice with plasmids encoding the entire sequences of NY-ESO-1 or MAGE-A4. CD8(+) T cells specific for NY-ESO-1 or MAGE-A4 were able to be detected by ELISPOT assays using antigen presenting cells pulsed with overlapping peptides covering the whole protein, indicating the high immunogenicity of these antigens in mice. Truncation of these peptides revealed that NY-ESO-1-specific CD8(+) T cells recognized D(d)-restricted 8mer peptides, NY-ESO-181-88. MAGE-A4
In developed countries, colorectal cancer (CRC) is a leading cause of cancer. Because this disease develops slowly over years and often starts with the apparition of polyps that may evolve in a malignant tumor, this cancer is particularly suitable for screening. However, current techniques of detection lack specificity and sensitivity, or are invasive, reducing the compliance of the patients. Thus, there is a need to find new biomarkers to improve the detection of CRC at an early stage and to reduce its incidence. In this work, we focused on autoantibodies (aAb) produced by the immune system as potential CRC biomarkers since they combine several advantages including stability, specificity and early production in the course of the disease. Human tumor-associated antigens (TAA) of interest were identified by the serological proteome analysis (SERPA) approach, based on the combination of 2D-gel electrophoresis and after transfer onto membranes, immunoblotting with sera from tumor-bearing mice or ...
Cancer testis (CT) antigens are promising targets for cancer immunotherapies such as cancer vaccines and genetically modified adoptive T cell therapy. In this study, we evaluated the expression of three CT antigens, melanoma-associated antigen A4 (MAGE-A4), New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) and sarcoma antigen gene (SAGE). MAGE-A4, NY-ESO-1 and/or SAGE antigen expression in tumour samples was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Informed consent was obtained from individuals prior to study enrolment. In total, 585 samples in 21 tumour types were evaluated between June 2009 and March 2018. The positive expression rates of these CT antigens were as follows: MAGE-A4, 34.6% (range, 30.7-38.7); NY-ESO-1, 21.0% (range, 17.2-25.1); and SAGE, 21.8% (range, 18.5-25.4). The MAGE-A4 antigen was expressed in 54.9% of oesophageal cancers, 37.5% of head and neck cancers, 35.0% of gastric cancers and 34.2% of ovarian cancers; the NY-ESO-1 antigen was
Sperm protein (Sp17) is an attractive target for ovarian cancer (OC) vaccines because of its over-expression in primary as well as in metastatic lesions, at all stages of the disease. Our studies suggest that a Sp17-based vaccine can induce an enduring defense against OC development in C57BL/6 mice with ID8 cells, following prophylactic and therapeutic treatments. This is the first time that a mouse counterpart of a cancer testis antigen (Sp17) was shown to be expressed in an OC mouse model, and that vaccination against this antigen significantly controlled tumor growth. Our study shows that the CpG-adjuvated Sp17 vaccine overcomes the issue of immunologic tolerance, the major barrier to the development of effective immunotherapy for OC. Furthermore, this study provides a better understanding of OC biology by showing that Th-17 cells activation and contemporary immunosuppressive T-reg cells inhibition is required for vaccine efficacy. Taken together, these results indicate that prophylactic and ...
The first tumor-specific shared antigens and the cancer-germline genes that code for these antigens were identified with antitumor cytolytic T lymphocytes obtained from cancer patients. A few HLA class I-restricted antigenic peptides were identified by this direct approach. A large set of additional cancer-germline genes have now been identified by purely genetic approaches or by screening tumor cDNA expression libraries with the serum of cancer patients. As a result, a vast number of sequences are known that can code for tumor-specific shared antigens, but most of the encoded antigenic peptides have not yet been identified. We review here recent reverse immunology approaches for the identification of new antigenic peptides. They are based on in vitro stimulation of naive T cells with dendritic cells that have either been loaded with a cancer-germline protein or that have been transduced with viruses carrying cancer-germline coding sequences. These approaches have led to the identification of many
A number of human tumor antigens have been characterized recently using cytolytic T lymphocytes (CTL) as screening tools. Some of them are encoded by MAGE-type genes, which are silent in normal tissues except in male germ cells, but are activated in a variety of tumors. These tumor-specific shared antigens appear to be promising targets for cancer immunotherapy. However, the choice of these antigens as targets has been questioned because of the lack of direct evidence that in vivo responses against such antigens can lead to tumor rejection. The antigen encoded by the mouse gene P1A represents the only available animal model system for MAGE-type tumor antigens. We show here that mice immunized by injection of L1210 leukemia cells expressing P1A and B7-1 (L1210.P1A.B7-1) are efficiently protected against a challenge with a lethal dose of mastocytoma P815 tumor cells, which express P1A. Mice immunized with L1210 cells expressing B7-1 but not P1A were not protected. Furthermore, we observed that P1A
Using the TCGA data set for malignant melanoma, the patients were segregated according to the presence or absence of the T cell-inflamed gene expression signature in the tumor microenvironment. Transcriptional profiling revealed no differences in the levels of cancer-testis (CT) antigens or differentiation antigens between the hot and the cold tumors. Using exome sequencing of tumor versus germline, a range of 18 to 3001 of non-synonymous mutations was observed in both cohorts. Using the syfpeithi algorithm for HLA-A*0201 patients, a median of 123 mutations having a high immunogenicity score were found in the T cell-inflamed cohort versus 176 in the non-T cell-inflamed. To confirm actual immunogenicity, 321 peptides from hot tumors and 409 peptides from cold tumors have been synthesized. Using a high-throughput T2 binding assay, peptides from both cohorts were found to bind to HLA-A*0201. In vitro priming of T cells using autologous dendritic cells also revealed that peptides from both cohorts ...
Abstract Background The lack of sufficient specificity and sensitivity among conventional cancer biomarkers, such as prostate specific antigen (PSA) for prostate cancer has been widely recognized after several decades of clinical implications. Autoantibodies (autoAb) among others are being extensively investigated as potential substitute markers, but remain elusive. One major obstacle is the lack of a sensitive and multiplex approach for quantifying autoAb against a large panel of clinically relevant tumor-associated antigens (TAA). Methods To circumvent preparation of phage lysates and purification of recombinant proteins, we identified B cell epitopes from a number of previously defined prostate cancer-associated antigens (PCAA). Peptide epitopes from cancer/testis antigen NY-ESO-1, XAGE-1b, SSX-2,4, as well as prostate cancer overexpressed antigen AMACR, p90 autoantigen, and LEDGF were then conjugated with seroMAP microspheres to allow multiplex measurement of autoAb present in serum samples. ...
Mass spectrometry helps identify antigens on tumor cells - posted in Immunology Products: Using an analytical technique called mass spectrometry (MS) that helps identify the chemical constitution of a substance, Angela M. Krackhardt and colleagues from Technische Universitat Munchen and collaborators identify novel target antigens for cancer intervention. Michal Bassani-Sternberg from Max Planck Institute of Biochemistry is the first author. CusAb offers protein. Immunotherapy works...
Alt. Names/Synonyms: ACSTD1; Adenocarcinoma-associated antigen; carcinoma-associated antigen GA733-2; Cell surface glycoprotein Trop-1; CO-17A; CO17-1A; DIAR5; EGP; EGP-2; EGP314; EGP34; EGP40; Ep-CAM; EPCAM; Epithelial cell adhesion molecule; Epithelial cell surface antigen; Epithelial glycoprotein; Epithelial glycoprotein 314; ESA; GA733-2; hEGP-2; hEGP314; HNPCC8; human epithelial glycoprotein-2; KS 1/4 antigen; KS1/4; KSA; M1S2; M4S1; Major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein); MIC18; MK-1; TACST-1; TACSTD1; TROP1; Tumor-associated calcium signal transducer 1 ...
Cancer treatment vaccines are designed to treat cancers that have already developed rather than to prevent them in the first place. Cancer treatment vaccines contain cancer-associated antigens to enhance the immune systems response to a patients tumor cells. The cancer-associated antigens can be proteins or another type of molecule found on the surface of or inside cancer cells that can stimulate B cells or killer T cells to attack them.. Some vaccines that are under development target antigens that are found on or in many types of cancer cells. These types of cancer vaccines are being tested in clinical trials in patients with a variety of cancers, including prostate, colorectal, lung, breast, and thyroid cancers. Other cancer vaccines target antigens that are unique to a specific cancer type (7-14). Still other vaccines are designed against an antigen specific to one patients tumor and need to be customized for each patient. The one cancer treatment vaccine that has received FDA approval, ...
PURPOSE: NY-ESO-1, one of the most immunogenic tumor antigens, is expressed in 15% to 25% of metastatic prostate cancers. The immunological and clinical effects of vaccination with recombinant NY-ESO-1 protein combined with CpG as adjuvant were evaluated. EXPERIMENTAL DESIGN: In a phase I clinical study, patients with advanced prostate cancer were vaccinated with recombinant NY-ESO-1 protein (100 μg) mixed with CpG 7909 (2.5 mg) every 3 weeks intradermally for 4 doses. Objectives of the study were the safety of the vaccine and changes of specific humoral and cellular immunological responses to NY-ESO-1 in relation to detectable NY-ESO-1 expression in the individual tumor. RESULTS: All 12 baseline sero-negative patients developed high-titer NY-ESO-1 antibody responses. B-cell epitope mapping identified NY-ESO-1 p91-110 to be recognized most frequently by vaccine-induced antibodies. Two patients developed significant antibody titers against the adjuvant CpG. NY-ESO-1-specific CD4+ and/or CD8+ ...
Cancer-Testis Antigens: -Smart- Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
The isolation of CD8+ cytolytic T cells (CTL) reactive to the autologous tumors in cancer patients has allowed, during the last decade, the identification of several categories of tumor-associated antigens that can be the target of tumor-specific immune responses. Among them, one of the most relevant for the development of cancer vaccines is the group of the so-called Cancer-Testis (CT) antigens, which are expressed by tumor cells but not by most somatic adult tissues, with the exception of testis. Because of their expression commonly found in tumors of various histological types, CT antigen-derived peptides recognized by tumor reactive CTL are relevant candidates for generic vaccination of cancer patients.. In the last two years, we have analyzed the natural response to four CT antigen-derived HLA-A2 restricted epitopes recognized by tumor reactive CTL. Three of them correspond to the previously described peptides from MAGE-A10 (254-262), NY-ESO-1 (157-165) and CAMEL (1-11). The fourth peptide ...
This gene is a member of the melanoma antigen gene (MAGE) family. Most of the genes of this family encode tumor specific antigens that are not expressed in normal adult tissues except testis. Although the protein encoded by this gene shares strong homology with members of the MAGE family, it is expressed in almost all normal adult tissues. This gene has been demonstrated to be involved in the p75 neurotrophin receptor mediated programmed cell death pathway. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008 ...
In this issue of Clinical Cancer Research, a new development in adoptive T-cell therapy experimental mouse tumor model is reported by Leisegang and colleagues (1).. In retrospect, the 1990s were considered a golden period for tumor immunology when many tumor antigens recognized by T cells were identified. The antigens reported by Boon and colleagues in both murine and human cancers (2, 3) were derived from genes that are overexpressed in cancer and fetal tissues (4). The second class of unmutated antigens recognized by tumor-reactive T cells is tissue-specific antigens that are also found in tumor cells (5). These unmutated tumor antigens were favored for cancer vaccines and cancer therapy because they are present in a high proportion of human cancers. However, the classical study by Prehn and Main (6) has cast a long shadow on the utility of the shared tumor antigen, as their in vivo analysis showed that tumor rejection antigens are by and large individually specific. In supporting this notion, ...
Principal Investigator:ARAKI Nobuhito, Project Period (FY):1995 - 1997, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Orthopaedic surgery
Three of nine patients (33%) remain in complete clinical remission at 25, 38, and 52 months, respectively. The cancer-testis antigen NY-ESO-1 is expressed in greater than 40% of advanced epithelial ovarian cancers and represents a promising immunotherapeutic target. In a small Phase I (safety and immunogenicity) clinical trial conducted by Memorial Sloan-Kettering Cancer Center and…
There is clear evidence that tumor patients are able to generate TAA-specific T cell immunity spontaneously. Whereas the presence of tumor-specific T cells has been shown by many groups and for various tumor types, much less is known about the function of TAA-specific T cells in vivo. Most of the TAAs including differentiation, germ-line, and shared overexpressed antigens are not tumor specific but are also expressed at low levels in certain nonmalignant tissues. This should influence the type of T cell response because deletion of functional high-avidity self-reactive T cells in the thymus as well as peripheral deletion or anergy was shown in various animal models (reviewed in Ref. 74 ). There are a few recent studies analyzing the functional avidity of TAA-specific T cells in patients. In leukemia patients, low-avidity T cells to proteinase 3, which are able to kill leukemia cells, can readily be expanded. However, high-avidity T cells can also be expanded from patients in cytogenetic ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Background: This study aimed to assess the prognostic value of receptor binding cancer antigen expressed on SiSo cells (RCAS1) expression and host immune response in gastric carcinomas. Methods: We i
ASN004 is an Antibody Drug Conjugate (ADC) that targets the 5T4 oncofetal antigen (trophoblast glycoprotein), which is highly expressed in a wide range of malignant tumors, while having very limited expression in normal tissues. ASN004 incorporates a novel single-chain homo-dimer antibody, Fleximer® linker technology (Mersana Therapeutics), and several cytotoxic dolastatin (auristatin) analog warheads per ADC molecule (drug/antibody ratio ∼15). ASN004 shows high affinity for the 5T4 antigen and for 5T4-expressing tumor cells. As well, ASN004 shows potent cytotoxicity that is selective for 5T4-expressing tumor cells. ASN004 provides strong tumor regression and tumor-free survivors in multiple tumor xenograft models, at well-tolerated doses as low as 0.3 mg/kg iv. Furthermore, ASN004 causes tumor regression when administered to xenografts bearing more advanced (500 mm3) tumors. Robust, potent efficacy for ASN004 has also been demonstrated in head-to-head comparison studies with relevant ...
As mentioned earlier, another aspect of cancer is a failure of the immune system to recognize tumor specific antigens. Cytokines behave similarly to growth factors, causing cells to grow and divide; however, they are the predominant cellular signals of the immune system and have other actions such as attaching (chemotaxis) white blood cells to the site of an infection. Interestingly, it has been shown cancer cells signal suppressor T cells to protect them from killer T cells against unique tumor antigens. The mechanism of recruitment is not fully understood but TGF-b and interleukin 10 (IL-10) have been implicated in regulatory T cell function. While some cytokines play a role in suppressing the immune system, others such as IL-2 play a role in activating the immune system. One of the strategies in battling cancer has been to exploit the ability of interleukin-2 (IL-2) to heighten the immune response. IL-2 has been shown to cause complete remission in 6% of patients with renal cancer ...
We have shown that both regressor and progressor clones can be isolated from a UV regressor tumor, RD-1024. Although the daughter clones are characterized by differences in tumorigenic potential in normal transplant hosts, they nevertheless seem to express the same major tumor rejection antigens, because immunization with either the regressor parent tumor, RD-1024, or with regressor Cl 8 protects against subsequent challenge with progressor C1 4 or Cl 9. Consistent with the in vivo-generated data is the evidence that draining lymph node cells with functional specificity for regressor Cl 8 are capable of cross-reactive cytotoxicity in an in vitro chromium release assay. We have demonstrated an indirect interaction occurring in vivo between regressor and progressor cells, in that Cl 8 cells have the ability to influence the outcome of simultaneous or sequential challenge with Cl 4 or Cl 9 cells. Because 500 rad of gamma irradiation has been shown to compromise the ability of mice to respond to a ...
In 2001, we have started compiling what we thought were the most relevant human tumor antigens, and created a database. Each line corresponds to a peptide, considered to be a tumor antigen given that it is recognized by T lymphocytes that also recognize tumor cells expressing the parent protein.
Objective(s): Multi-epitopic protein vaccines and direction of vaccine delivery to dendritic cells (DCs) are encouraging approaches for enhancing immune system reactions against mutable pathogens. The very best cultivation condition for creation of HIVtop4 proteins can be induction by 1 mM IPTG during 4 hr in 2XYT moderate. The final focus of purified proteins was 500 g/ml. genome offers led to Vandetanib the introduction of vaccines incorporating just these essential epitopes to be able to elicit the mandatory immunologic response (5, 6). These epitope centered vaccines possess potential benefits like as biosafety, exact control over Vandetanib the disease fighting capability activation and capability of concentrate on conserved and extremely immunogenic antigen areas (7). Among the HIV-1 antigens, Gag, Tat, Env and Pol have obtained substantial interest because of the essential tasks in viral existence routine (8, 9), and also have sites in the viral genome mapping to both T helper and T ...
Cytolytic CD8 T cells fall into two subpopulations based on cytokine-secretion. Type 1 CD8 cells Tc1 characteristically secrete IFN-gamma, whereas type 2 CD8 cells Tc2 secrete ILA and IL- 5. Using a TSA mammary carcinoma cell line, expressing HA as a surrogate tumor-associated antigen, we assessed the therapeutic effects of adoptively transferred HA tumor-specific Tc1 and Tc2 effector cells in mice with established malignancy. Both Tc1 and Tc2 subpopulations effectively delayed tumor cell growth and mediated tumor regression in mice with established malignancy. Flow cytometric analysis showed that donor cells accumulated at the tumor site and antitumor effects were highly tumor specific. First-line treatment with either methotrexate MTX or 5-Fluorouracil 5-FU chemotherapeutic agents markedly enhanced the co- therapeutic effects of Tc2 effector cells. Whereas, MTX but not 5-FU, acted synergistically with corresponding Tc1 immunotherapy. Although effector cell therapies in combination with chemotherapy
PRP31_HUMAN RecName: Full=U4/U6 small nuclear ribonucleoprotein Prp31; AltName: Full=Pre-mRNA-processing factor 31; AltName: Full=Serologically defined breast cancer antigen NY-BR-99; AltName: Full=U4/U6 snRNP 61 kDa protein; Short=Protein 61K; Short=hPrp31 ...
Tikcro Technologies Ltd., powered by a novel 3D antigen design technology, generates new ‎antibodies that block receptor/ligand surface domains of immune modulators and re-‎activate the bodys immune system to fight cancer. Our antibodies are in various pre-‎clinical stages.. Following extensive collaborative research with the Weizmann Institute of Science in ‎Israel, we are developing drug-candidates by leveraging a unique antigen design ‎technology for the generation of new functional blocking antibodies. This approach has ‎shown early success with pipeline below. Going forward, in 2017-2018 we plan to advance ‎with early-stage candidates to rigorous pre-clinical trials and aim to build sufficient data for ‎further progress and clinical trials.‎. ...
Janelle, Valérie; Lamarre, Alain (2014). How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity? Frontiers in oncology , vol. 4 , nº 135. p. 1-3. DOI: 10.3389/fonc.2014.00135. ...
TROP2 belongs to the TACSTD family and is a cell surface glycoprotein encoded by the TACSTD2 gene. It is also known as tumor-associated calcium signal transducer 2 (TACSTD2), epidermal glycoprotein 1 (EGP-1), and gastrointestinal tumor-associated antigen (GA733-1) and surface mar
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30 ...
Zdroj: Immunol Lett. 2020 Mar;219:46-53. doi: 10.1016/j.imlet.2020.01.001. Epub 2020 Jan 10. Authors: O. Palata, N. Podzimkova Hradilova, D. Mysiková, B. Kutna, H. Mrazkova, R. Lischke, R. Spisek, I. Adkins. ...
Squamous cell carcinoma antigen: a role in the early identification of nodal metastases in men with squamous cell carcinoma of the penis. To evaluate whether serum squamous cell carcinoma antigen (SCCAg) measurements may be of use in identifying nodal metastases in patients with SCC of the penis after treating the primary tumour. The levels of SCCAg were analysed in 11 men with penile SCC between 1994 and 2001. An elevated SCCAg level had a sensitivity of 57% (95% confidence interval, CI, 18-90%) and a specificity of 100% (CI 40-100%) for nodal metastases. Levels of SCCAg increased exponentially in patients who developed nodal metastases after treatment of the primary tumour, and were elevated before clinical or radiological evidence of nodal disease. Either the absolute level or the rate of rise of SCCAg may be a useful tool with which to follow patients after excision of the primary tumour. It may be more sensitive than computed tomography and magnetic resonanc imaging in detecting recurrence, ...
Our analysis of cervical cancer patients treated with CCRT indicated that the sensitivity and specificity of two consecutive increases in serum SCC-Ag for predicting tumor recurrence were 61.1% and 97.9%, respectively. These results are comparable to previously reported results. For example, several studies of cervical cancer patients showed that an elevated serum SCC-Ag level was associated with 70-92% rate of recurrent tumors [8, 11, 14-19]; in addition, the specificity of SCC-Ag during the follow-up period was quite high, varying from 95 to 98% [7, 16, 20]. According to our ROC analysis, the area under the ROC curve indicated the ΔSCC-Ag was 0.83 for patients who had elevated pre-treatment SCC-Ag. Therefore, our results indicate that ΔSCC-Ag had good clinical performance in detection of recurrent disease.. As described above, we defined biochemical failure as two consecutive SCC-Ag values above normal. There are no standard criteria used to define biochemical failure in cervical cancer, and ...
TY - JOUR. T1 - Carbonic anhydrase IX expression in renal neoplasms. T2 - Correlation with tumor type and grade. AU - Genega, Elizabeth M.. AU - Ghebremichael, Musie. AU - Najarian, Robert. AU - Fu, Yineng. AU - Wang, Yihong. AU - Argani, Pedram. AU - Grisanzio, Chiara. AU - Signoretti, Sabina. PY - 2010/12. Y1 - 2010/12. N2 - Carbonic anhydrase IX (CAIX), a hypoxia-induced protein, is expressed in some renal tumors. We evaluated its immunohistochemical expression in 317 primary and 42 metastatic renal neoplasms (186 clear cell, 52 papillary, 35 chromophobe, 47 unclassified, and 15 Xp11.2 translocation renal cell carcinomas [RCCs]; 26 oncocytomas; 2 metanephric adenomas; 1 urothelial carcinoma; 1 mixed epithelial and stromal tumor; and 1 angiomyolipoma); 7 neoplasms were unknown as to whether they were primary or metastatic. We also correlated expression with tumor type and grade. Variable staining was seen in clear cell, papillary, unclassified, and Xp11.2 translocation carcinomas. One ...
PURPOSE: To evaluate carbonic anhydrase (CA) IX as a surrogate marker of hypoxia and investigate the prognostic significance of different patterns of expression in non-small-cell lung cancer (NSCLC). METHODS: Standard immunohistochemical techniques were used to study CA IX expression in 175 resected NSCLC tumors. CA IX expression was determined by Western blotting in A549 cell lines grown under normoxic and hypoxic conditions. Measurements from microvessels to CA IX positivity were obtained. RESULTS: CA IX immunostaining was detected in 81.8% of patients. Membranous (m) (P =.005), cytoplasmic (c) (P =.018), and stromal (P |.001) CA IX expression correlated with the extent of tumor necrosis (TN). The mean distance from vascular endothelium to the start of tumor cell positivity was 90 micro m, which equates to an oxygen pressure of 5.77 mmHg. The distance to blood vessels from individual tumor cells or tumor cell clusters was greater if they expressed mCA IX than if they did not (P |.001). Hypoxic
TY - JOUR. T1 - Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. AU - Mortarini, Roberta. AU - Borri, Alessandra. AU - Tragni, Gabrina. AU - Bersani, Ilaria. AU - Vegetti, Claudia. AU - Bajetta, Emilio. AU - Pilotti, Silvana. AU - Cerundolo, Vincenzo. AU - Anichini, Andrea. PY - 2000/7/1. Y1 - 2000/7/1. N2 - Systemic effects on T-cell-mediated antitumor immunity, on expression of T-cell adhesion/homing receptors, and on the promotion of T-cell infiltration of neoplastic tissue may represent key steps for the efficacy of immunological therapies of cancer. In this study, we investigated whether these processes can be promoted by s.c. administration of low-dose (0.5 μg/kg) recombinant human interleukin-12 (rHuIL-12) to metastatic melanoma patients. A striking burst of HLA-restricted CTL precursors (CTLp) directed to autologous tumor was documented in peripheral blood by a ...
The protein encoded by this gene is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. This gene product is found to be an important cellular factor for HIV-1 gene expression and viral replication. It also associates transiently with U6 and U4/U6 snRNPs during the recycling phase of the spliceosome cycle. This encoded protein is thought to be involved in the regulation of mRNA splicing. [provided by RefSeq, Jul 2008 ...
TY - JOUR. T1 - Surface Marker Epithelial Cell Adhesion Molecule and E-cadherin Facilitate the Identification and Selection of Induced Pluripotent Stem Cells. AU - Chen, Hsin Fu. AU - Chuang, Ching Yu. AU - Lee, Wen Chih. AU - Huang, Hsiang Po. AU - Wu, Han Chung. AU - Ho, Hong Nerng. AU - Chen, Yu Ju. AU - Kuo, Hung Chih. PY - 2011/9/1. Y1 - 2011/9/1. N2 - The derivation of induced pluripotent stem cells (iPSCs) requires not only efficient reprogramming methods, but also reliable markers for identification and purification of iPSCs. Here, we demonstrate that surface markers, epithelial cells adhesion molecule (EpCAM) and epithelial cadherin (E-cadherin) can be used for efficient identification and/or isolation of reprogrammed mouse iPSCs. By viral transduction of Oct4, Sox2, Klf4 and n- or c-Myc into mouse embryonic fibroblasts, we observed that the conventional mouse embryonic stem cell (mESC) markers, alkaline phosphatase (AP) and stage-specific embryonic antigen 1 (SSEA1), were expressed in ...
Buy Psca recombinant protein, Prostate stem cell antigen Recombinant Protein-P57096.1 (MBS962351) product datasheet at MyBioSource, Recombinant Proteins
Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer.: We found that high P
Human being epithelial cell adhesion molecule (HEPCAM) is a tumor-associated antigen frequently expressed in carcinomas, which promotes proliferation after controlled intramembrane proteolysis. which can be connected with mutations from the gene (9). Although Lei (8) reported a particular amount of embryonic lethality, the nice known reasons for these obvious discrepancies in phenotypes stay unknown. Furthermore, molecular systems in charge of the noticed Bay 11-7821 congenital tufting enteropathy phenotypes had been deviating. Guerra (7) suggested a job for adherens junctions having a mislocalization of E-cadherin and -catenin in the developing intestine (7), whereas Lei (8) excluded the participation of E-cadherin and -catenin, which were located properly, and a function was stated by them for mEpcam in the recruitment Bay 11-7821 of claudins to tight junctions. A job for Epcam in the forming of practical adherens junctions via E-cadherin was further referred to during epiboly Rabbit ...
Cancer testis antigens (CTAs) are expressed in a variety of malignant tumors but not in any normal adult tissues except germ cells and occasionally placenta. Because of this tumor-associated pattern of expression, CTAs are regarded as potential vaccine targets. The expression of CTAs in gastrointestinal stromal tumors (GIST) has not been analyzed systematically previously. The present study was performed to analyze the expression of CTA in GIST and to determine if CTA expression correlates with prognosis. Thirty-five GIST patients were retrospectively analyzed for their expression of CTAs by immunohistochemistry using the following monoclonal antibodies (mAb/antigen): MA454/MAGE-A1, M3H67/MAGE-A3, 57B/MAGE-A4, CT7-33/MAGE-C1 and E978/NY-ESO-1. Fourteen tumors (40%) expressed 1 or more of the 5 CTAs tested. Fourteen percent (n = 5/35) were positive for MAGE-A1, MAGE-A3 or MAGE-A4, respectively. Twenty-six percent (n = 9/35) stained positive for MAGE-C1 and 20% (n = 7/35) for NY-ESO-1. A
As a leading supplier of innovative life science research tools, Creative Diagnostics continues to expand its products portfolio by offering of unique antigens for researchers globally, which is supported by extensive research, development, and validation for superior quality. The addition of antigen products and services will enable scientists to work on more specific projects, and also provide leading researchers and diagnostic manufacturers with a more diverse antigen selection, which facilitates the development of assays with greater specificity and sensitivity.. These newly released antigens are rigorously tested to meet the demand in research and development and are featured with excellent quality, including Viral Antigens, Bacterial Antigens, Fungal Antigens, Parasitic Antigens, Immunoglobulin, Hapten, Cardiac Biomarkers and so on. With this expanded offering of antigens products, Creative Diagnostics enables scientists to achieve more complete analysis experiments. These products along ...
Background: The delivery of specific immunotherapies for malignant tumours requires the identification of relevant tumour antigens and sequences from these which can be used to stimulate protective T cell-mediated immunity. HAGE (DDX43) is a cancer testis antigen belonging to the DEAD box family of helicases found by our group to be over-expressed in many solid cancers including breast cancer (Mathieu et al.1) immunogenic (Mathieu et al.2 and to be a biomarker for poor prognosis as well as a predictor of chemotherapy response in breast cancer (Abdel-fatah et al.3). We propose that HAGE might be a novel immunotherapeutic target for patients bearing breast cancers expressing this antigen. The aim of this study is to identify strongly immunogenic HAGE-derived sequences which can be used for the development of a therapeutic vaccine for HAGE positive cancer.. Experimental Design: The HAGE-derived sequences were identified and assessed after: (i) using a computer-based epitope predictive tool; (ii) ...
Human melanoma antigen (MAGE) genes have been shown to be expressed in both normal tissues and in various tumors and tumor related cells. Two types of MAGE genes have been characterized based on their expression: type-I members are silent in all normal tissues except for in the male germ line and placenta while type-II members are expressed ubiquitously in both tumor and normal cells (Figure 1). MAGE-C subfamily members are type-I genes expressed in various tumor types; their proteins are tumor-specific antigens that can be recognized by cytolytic T lymphocytes. MAGE-D subfamily members are type-II members they do not encode for those tumor-specific antigens seen in type-I MAGE and are also expressed ubiquitously in normal adult tissues. While MAGE genes could be targets for immunotherapy, information on the function and expression pattern of MAGE-C and MAGE D genes, however, remains incomplete. Analysis of the gene expression of type-I and type-II MAGE genes in various histological tumors may ...
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating Ca2+-independent homotypic cell-cell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc, e-fabp, and cyclins A & E. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. It appears to play a role in tumorigenesis and metastasis of carcinomas, so it can also act as a potential prognostic marker and as a potential target for immunotherapeutic strategies. First discovered in 1979, EpCAM was initially described as a dominant surface antigen on human colon carcinoma. Because of its prevalence on many carcinomas, it has been discovered many different times. EpCAM therefore has many aliases the most notable of which include TACSTD1 (tumor-associated calcium signal transducer 1), CD326 ...
A discovery by scientists working with the Health Sciences Initiative could lead the way to a vaccine against prostate cancer. The researchers, led by immunologist James Allison, a Howard Hughes Medical Institute investigator and professor of molecular and cell biology, found a protein on prostate cancer cells that tips off the immune system to the tumor s presence and brings in an armada of immune cells to destroy it.. If the protein, called an antigen, is truly unique to prostate cancer cells, it could lead to diagnostics for prostate cancer and a potential vaccine therapy against the disease, which is the second leading cause of cancer death in men, after lung cancer. This is the first prostate cancer antigen found.. The hope is twofold, Allison said. One, knowing what the specific target of the immune system is, we can do some very direct studies of whether it is a prognosticator of favorable outcome of disease. And two, we can start thinking about using the antigens to develop a specific ...
The human pancarcinoma-associated epithelial cell adhesion molecule (EpCAM) (EGP-2, CO17-1A) is a well-known target for carcinoma-directed immunotherapy. Mouse-derived mAbs directed to EpCAM have been used to treat colon carcinoma patients showing well-tolerable toxic side effects but limited antitu …
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Because tumor-specific cytotoxic T lymphocytes (CTL) recognize tumor antigen associated with MHC class I molecules expressed on the tumor surface, any alteration in the tumor antigen processing and presentation will greatly affect CTL immunity. In fact, downregulation or complete loss of MHC I molecules have been demonstrated in a wide array of tumors, particularly prostate, colon, lung, and breast cancers (5-12). Disruption or downregulation of antigen processing components, such as TAP (transporters associated with antigen processing) and LMP (components of the proteasome complex) genes have also been observed in several tumor types, including breast, prostate, and renal cancers (13-15). Another tactic tumors exploit is downregulation or alteration of tumor antigens. Several independent research groups described the loss of melanoma-associated antigen either during treatment by adoptive transfer of ex vivo expanded antigen-specific CTL (16) or during immune therapy by tumor vaccinations ...
Recombinant Human Epithelial cell adhesion molecule(EPCAM),partial von Cusabio bei SZABO-SCANDIC erhältlich. Weiteres zu Proteine & Peptide finden Sie hier.
Recombinant Human Epithelial cell adhesion molecule(EPCAM),partial von Cusabio bei SZABO-SCANDIC erhältlich. Weiteres zu Proteine & Peptide finden Sie hier.
NY-ESO-1 is a human tumor antigen of the cancer/testis family. It is highly expressed in many poor-prognosis melanomas. It is being studied as possible target for a cancer vaccine or immunotherapy. It is a target for some experimental engineered T-cell therapies for myeloma. Lloyd J. Old#Major Discoveries Gnjatic, S; et al. (2006). NY-ESO-1: review of an immunogenic tumor antigen. Advances in Cancer Research. 95: 1-30. doi:10.1016/S0065-230X(06)95001-5. PMID 16860654. van Rhee, F (15 May 2005). NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses (PDF). Blood. 105 (10): 3939-3944. doi:10.1182/blood-2004-09-3707. PMC 1895070 . PMID 15671442. Rapoport, AP; et al. (20 July 2015). NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine. 21 (8): 914-921. doi:10.1038/nm.3910. PMC 4529359 . PMID 26193344. A novel human-derived antibody against NY-ESO-1 ...
Y-box binding protein 2 (YBX2) has been associated with the properties of both germ cells and cancer cells. We hypothesized that YBX2 might contribute to the characteristics of cancer stem cells (CSCs). In this study, we clarified the function of YBX2 in endometrial cancer stem cells. We established a human YBX2-expressing Ishikawa (IK) cell line (IK-YBX2 cells). We analyzed gene expression associated with stemness and isolated SP cells from IK-YBX2 cells. The SP population of IK-YBX2 cells, the expression of ALDH1 and serial sphere-forming capacity were associated with levels of YBX2 expression. IK-YBX2 cells were resistant to anti-cancer drugs. In gene expression analysis, a gene for cancer testis antigen, CT45, was generally overexpressed in IK-YBX2 cells. YBX2-mediated CT45 expression was associated with increased levels of self-renewal capacity and paclitaxel resistance. The level of CT45 expression was enhanced in high-grade and/or advanced stages of human endometrial cancer tissues. We conclude
0192] Numerous tumor antigens are known in the art, including: (a) cancer-testis antigens such as NY-ESO-1, SSX2, SCP1 as well as RAGE, BAGE, GAGE and MAGE family polypeptides, for example, GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, and MAGE-12 (which can be used, for example, to address melanoma, lung, head and neck, NSCLC, breast, gastrointestinal, and bladder tumors), (b) mutated antigens, for example, p53 (associated with various solid tumors, e.g., colorectal, lung, head and neck cancer), p21/Ras (associated with, e.g., melanoma, pancreatic cancer and colorectal cancer), CDK4 (associated with, e.g., melanoma), MUM1 (associated with, e.g., melanoma), caspase-8 (associated with, e.g., head and neck cancer), CIA 0205 (associated with, e.g., bladder cancer), HLA-A2-R1701, beta catenin (associated with, e.g., melanoma), TCR (associated with, e.g., T-cell non-Hodgkins lymphoma), BCR-abl (associated with, e.g., chronic myelogenous leukemia), triosephosphate isomerase, KIA ...
Treatment with the demethylating agent 5-Azacytidine leads to prolonged survival for patients with myelodysplastic syndrome, and the demethylation induces upregulation of cancer-testis antigens. Cancer-testis antigens are well-known targets for immune recognition in cancer, and the immune system may have a role in this treatment regimen. We show here that 5-Azacytidine treatment leads to increased T-cell recognition of tumor cells. T-cell responses against a large panel of cancer-testis antigens were detected before treatment, and these responses were further induced upon initiation of treatment. These characteristics point to an ideal combination of 5-Azacytidine and immune therapy to preferentially boost T-cell responses against cancer-testis antigens. To initiate such combination therapy, essential knowledge is required about the general immune modulatory effect of 5-Azacytidine. We therefore examined potential treatment effects on both immune stimulatory (CD8 and CD4 T cells and Natural ...
Gastric cancers are responsible for the second most cancer-related deaths worldwide. Although medical and surgical treatments have improved for gastric cancers, survival rates remain poor for both lung and gastric cancer patients.. Currently, approaches for immunotherapy in gastric cancer rely on the use of immunocytes, white blood cells that produce antibodies or trigger an immune response. Specifically, the current immunotherapy is designed to activate tumor specific cytotoxic T cells or to specifically bind target molecules or proteins expressed on the malignant tumor cells. In their research, a number of tumor rejection antigens have also been identified.. Experimental vaccination strategies are also in trial, including use of whole protein and peptide vaccines based on identification of peptides recognized by cytotoxic T lymphocytes and helper T lymphocytes. Tumor rejection antigens are selectively expressed in human tumors including gastric cancer, which can be recognized by cytotoxic T ...
TY - JOUR. T1 - MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. AU - Yang, Bing. AU - OHerrin, Sean M.. AU - Wu, Jianqiang. AU - Reagan-Shaw, Shannon. AU - Ma, Yongsheng. AU - Bhat, Kumar M.R.. AU - Gravekamp, Claudia. AU - Setaluri, Vijayasaradhi. AU - Peters, Noel. AU - Hoffmann, F. Michael. AU - Peng, Hongzhuang. AU - Ivanov, Alexey V.. AU - Simpson, Andrew J.G.. AU - Longley, B. Jack. N1 - Copyright: Copyright 2009 Elsevier B.V., All rights reserved.. PY - 2007/10/15. Y1 - 2007/10/15. N2 - The MAGE-A, MAGE-B, and MAGE-C protein families comprise the class-I MAGE/cancer testes antigens, a group of highly homologous proteins whose expression is suppressed in all normal tissues except developing sperm. Aberrant expression of class I MAGE proteins occurs in melanomas and many other malignancies, and MAGE proteins have long been recognized as tumor-specific targets; however, their functions have largely been unknown. ...
Human B melanoma antigen ELISA Kit;Human antigen MZ2-BA ELISA Kit;Human cancer/testis antigen 2.1 ELISA Kit;Human CT2.1 ELISA Kit;Human BAGE1 ELISA Kit;Human B melanoma antigen 1 ELISA Kit;Human cancer/testis antigen family 2, member 1 ELISA Kit ...
Vaccines that prevent disease have profoundly changed the lives of billions of people around the world, says Matthew M. Davis, M.D., MAPP, associate professor of pediatrics and internal medicine at the University of Michigan Medical School. A national strategy for therapeutic cancer vaccines would help emphasize development and regulatory approval for vaccines targeting cancers that currently do not have other good therapeutic options ...
Much has been learned in recent years concerning the nature of tumor antigens recognized by T cells. To apply this knowledge clinically, the nature of the host response to individual and multiple tumor antigens has to be characterized. This will help to define the efficacy of immune surveillance and the immune status of the host following exposure to tumor antigens expressed on pre-neoplastic tissue. To approach these questions, we have developed a transgenic mouse which expresses the tumor-specific antigen P91A. The single amino acid substitution in P91A results in the expression of a new MHC class I (H-2Ld)-binding peptide. In transgenic tissue, the H-2Ld/P91A complex is expressed in isolation from other tumor-associated antigens, allowing definition of the immune response to a single defined tumor antigen, a situation closely analogous to events during tumorigenesis. We show that CD8+ T cell immune surveillance of P91A is ineffective without the introduction of a helper determinant operating ...
Complete cancer regression occurs in a subset of patients following adoptive T cell therapy (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs). However, the low success rate presents a great challenge to broader clinical application. To provide insight into TIL-based immunotherapy, we studied a successful case of ACT where regression was observed against tumors carrying the hotspot mutation G12D in the KRAS oncogene. Four T cell receptors (TCRs) made up the TIL infusion and recognized two KRAS-G12D neoantigens, a nonamer and a decamer, all restricted by human leukocyte antigen (HLA) C*08:02. Three of them (TCR9a, 9b, and 9c) were nonamer-specific, while one was decamer-specific (TCR10). We show that only mutant G12D but not the wild-type peptides stabilized HLA-C*08:02 due to the formation of a critical anchor salt bridge to HLA-C. Therapeutic TCRs exhibited high affinities, ranging from nanomolar to low micromolar. Intriguingly, TCR binding affinities to HLA-C inversely correlated ...
Multiple intravenous injections of a cDNA library, derived from human melanoma cell lines and expressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with established melanoma tumors. Successful tumor eradication was associated with the ability of mouse lymphoid cells to mount a tumor-specific CD4 + interleukin (IL)-17 recall response in vitro. We used this characteristic IL-17 response to screen the VSV-cDNA library and identified three different VSV-cDNA virus clones that, when used in combination but not alone, achieved the same efficacy against tumors as the complete parental virus library. VSV-expressed cDNA libraries can therefore be used to identify tumor rejection antigens that can cooperate to induce anti-tumor responses. This technology should be applicable to antigen discovery for other cancers, as well as for other diseases in which immune reactivity against more than one target antigen contributes to disease pathology. © 2012 Nature America, Inc. ...
The data presented here point to an active cooperation between CD4+ and CD8+ T cells in the eradication of tumor cells. The adoptive transfer of CD4+ T cells has been reported to treat established tumor (17, 18, 19); however, CD4+ T cells in these systems were hypothesized to act through NK or macrophage effector cells or by direct lysis of a MHC class II-positive tumor. Ossendorp et al. have found that generation of specific CD4+ T cells through immunization with a helper epitope resulted in increased anti-tumor activity that is mediated by CD8+ effector cells, even when the tumor cells used are MHC class II negative (20). The present manuscript is the first in which the transfer of CD4+ T cells specific for a model tumor Ag have been found to elicit the de novo generation of CD8+ T cells specific for that same Ag.. CD8+ T cells have been widely reported to transfer tumor immunity and to treat established tumors upon adoptive transfer (21, 22). They are thought to work by directly destroying ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
My research has focused on the discovery and clinical development of novel cancer immunotherapeutics targeting the self/tumor antigen guanylyl cyclase C (GUCY2C; GCC). Current research projects focus on:. 1. Cancer Mucosa Antigens as Immunotherapeutic Targets for Metastatic Tumors. Immunotherapy for human cancers is hindered, in part, by a lack of suitable target antigens. This is particularly relevant in tumors derived from mucosal tissues such as colorectal cancer, in which antigens that are sufficiently immunogenic, tumor-restricted and shared among patients are lacking, and for which conventional therapeutics are poorly efficacious. We have explored a novel class of tumor-associated antigens fulfilling these criteria by exploiting immune compartmentalization, which restricts cross-talk between systemic and mucosal immune compartments. This compartmentalization limits systemic tolerance to mucosa-restricted self-antigens and shields mucosa from systemic autoimmune responses. Thus, a novel ...
Antibody Panel to Epithelial Cell Surface Antigen EpCAMAcris Antibodies offers a full range of thoroughly evaluated antibodies for specific detection…
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC - Pipeline Review, H1 2019
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. This MAGEA gene encodes a protein that is C-terminally truncated compared to other family members, and this gene can be alternatively interpreted to be a pseudogene. The protein is represented in this Gene record in accordance with the assumed protein-coding status defined in the literature. Read-through transcription exists between this gene and the upstream melanoma antigen family A, 10 (MAGEA10) gene.
NY-ESO-1 and LAGE-1 are cancer testis antigens with an ideal profile for tumor immunotherapy, combining up-regulation in many cancer types with highly restricted expression in normal tissues and sharing a common HLA-A*0201 epitope, 157-165. Here, we present data to describe the specificity and anti-tumor activity of a bifunctional ImmTAC, comprising a soluble, high-affinity T-cell receptor (TCR) specific for NY-ESO-1157-165 fused to an anti-CD3 scFv. This reagent, ImmTAC-NYE, is shown to kill HLA-A2, antigen-positive tumor cell lines, and freshly isolated HLA-A2- and LAGE-1-positive NSCLC cells. Employing time-domain optical imaging, we demonstrate in vivo targeting of fluorescently labelled high-affinity NYESO-specific TCRs to HLA-A2-, NYESO- 1157-165-positive tumors in xenografted mice. In vivo ImmTAC-NYE efficacy was tested in a tumor model in which human lymphocytes were stably co-engrafted into NSG mice harboring tumor xenografts; efficacy was observed in both tumor prevention and ...
Sigma-Aldrich offers abstracts and full-text articles by [Achim A Jungbluth, Scott Ely, Maurizio DiLiberto, Ruben Niesvizky, Barbara Williamson, Denise Frosina, Yao-Tseng Chen, Nina Bhardwaj, Selina Chen-Kiang, Lloyd J Old, Hearn Jay Cho].
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
Tumor-associated antigens (TAA) are monomorphic self-antigens that are proposed as targets for immunotherapeutic approaches to treat malignancies. We investigated whether T cells with sufficient avidity to recognize naturally overexpressed self-antigens in the context of self-HLA can be found in the T-cell repertoire of healthy donors. Minor histocompatibility antigen (MiHA)-specific T cells were used as model, as the influence of thymic selection on the T-cell repertoire directed against MiHA can be studied in both self (MiHApos donors)and non-self (MiHAneg donors) backgrounds. T-cell clones directed against the HLA*02:01-restricted MiHA HA-1H were isolated from HA-1Hneg/HLA-A*02:01pos and HA-1Hpos/HLA-A*02:01pos donors. Of the 16 unique HA-1H-specific T-cell clones, 5 T-cell clones derived from HA-1Hneg/HLA-A*02:01pos donors and 1 T-cell clone derived from an HA-1Hpos/HLA-A*02:01pos donor showed reactivity against HA-1Hpos target cells. Additionally, in total 663 T-cell clones (containing at ...
The human MAGE genes are expressed in a wide variety of tumors but not in normal cells, with the exception of the male germ cells, placenta, and, possibly, cells of the developing embryo. These genes encode tumor-specific antigens recognized by cytolytic T lymphocytes. The MAGE genes are located on …
Normally, B-cells take up foreign antigens, move to the germinal centers of secondary lymphoid organs such the spleen and lymph ... Lymphoid neoplasms with plasmablastic differentiation were classified by the World Health Organization, 2017 as a sub-grouping ... In cases so infected, the lymphoid neoplasm may result, at least in part, from this viral infection and therefore can be ... The lymphoid neoplasms with plasmacytic differentiation are: 1) Plasmablastic lymphoma: The most common of these lymphoid ...
"Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms". Clinical Cancer Research. 9 (17): ... Melanoma-associated antigen 4 is a protein that in humans is encoded by the MAGEA4 gene. This gene is a member of the MAGEA ... May 2006). "Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung ... Rogner UC, Wilke K, Steck E, Korn B, Poustka A (October 1995). "The melanoma antigen gene (MAGE) family is clustered in the ...
Manolios N, Kemp O, Li ZG (1994). "The T cell antigen receptor alpha and beta chains interact via distinct regions with CD3 ... Dyer MJ (1989). "T-cell receptor delta/alpha rearrangements in lymphoid neoplasms". Blood. 74 (3): 1073-83. doi:10.1182/blood. ... Chilson OP, Kelly-Chilson AE (1989). "Mitogenic lectins bind to the antigen receptor on human lymphocytes". Eur. J. Immunol. 19 ...
CD1+Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... CD4 continues to be expressed in most neoplasms derived from T helper cells. It is therefore possible to use CD4 ... The antigen has also been associated with a number of autoimmune diseases such as vitiligo and type I diabetes mellitus. T- ... CD4 is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells. The ...
Thymoma is a common neoplasm arising from the thymus, the primary lymphoid organ where T cells become educated to distinguish " ... abnormal thymic education occurs as a result of subtle differences in antigen processing. In TAMA these differences result in ...
... or monoclonal antibody termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. They can be of diagnostic ... Proliferating cell nuclear antigen (PCNA) is a DNA clamp that acts as a processivity factor for DNA polymerase δ in eukaryotic ... PCNA was originally identified as an antigen that is expressed in the nuclei of cells during the DNA synthesis phase of the ... Webb G, Parsons P, Chenevix-Trench G (1991). "Localization of the gene for human proliferating nuclear antigen/cyclin by in ...
All of these antigens are present in specific neuronal cell types. With these we can define anatomical circuits with a high ... In pathological conditions was also reported that glial neoplasms and reactive glial cells expressed this marker. Calretinin is ... Neuronal Nuclei antigen (NeuN) or Fox-3 is a nuclear protein present in postmitotic cell, at the point of differentiation into ... Lavezzi, A. M.; Corna, M. F.; Matturri, L. (2013). "Neuronal nuclear antigen (NeuN): a useful marker of neuronal immaturity in ...
By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ... In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to ... The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells ... A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with ...
In humans, pDCs exhibit plasma cell morphology and express CD4, HLA-DR, CD123, blood-derived dendritic cell antigen-2 (BDCA-2 ... Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... Unlike myeloid dendritic cells, myeloid antigens like CD11b, CD11c, CD13, CD14 and CD33 are not present on pDC surfaces. ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the ...
As a weak, biphasic antibody, it absorbs to the P antigen in the cold temperature as in the periphery in the primary phase, and ... as well as hematological malignancies including non-Hodgkin lymphoma and myeloproliferative neoplasms. The exact pathogenesis ... Indirect DL test with addition of ABO-compatible P antigen-positive blood can be performed in case the direct DL test is ... The hallmark feature is the formation of polyclonal IgG autoantibody against the P antigen, which is a polysaccharide surface ...
... neoplasms including sarcomas such as hemangiopericytoma and malignant peripheral nerve sheath tumor in ... providing the ground for starting inflammatory and immune responses upon the detection of antigens.: 161 There are many types ...
List of specialized glands within the human integumentary system List of target antigens in pemphigoid List of target antigens ... Many cutaneous neoplasms occur in the setting of systemic syndromes. List of cutaneous conditions List of contact allergens ... PMID 23426075 Baranov E, Hornick JL (March 2020). "Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the ...
... integumentary system List of target antigens in pemphigoid List of target antigens in pemphigus The most common benign neoplasm ... The most common malignant neoplasm is a basal cell carcinoma. Bolognia, Jean L.; et al. (2007). Dermatology. St. Louis: Mosby. ...
... and it is at this latter stage that CD3 antigen begins to migrate to the cell membrane. The antigen is found bound to the ... and can therefore be used to distinguish them from superficially similar B-cell and myeloid neoplasms. Zheng L, Lin J, Zhang B ... Mouse CD Antigen Chart Human CD Antigen Chart (Articles with short description, Short description matches Wikidata, Articles ... ISBN 978-1-4377-1528-6. Media related to CD3 (immunology) at Wikimedia Commons CD3+Antigens at the US National Library of ...
... making it possible to use the presence of the antigen to distinguish these conditions from B cell neoplasms. Due to its ... CD2+Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... It has also been called T-cell surface antigen T11/Leu-5, LFA-2, LFA-3 receptor, erythrocyte receptor and rosette receptor. It ... Luzzati AL, Giacomini E, Giordani L, Pugliese O, Viora M, Chersi A (1992). "The antigen-specific induction of normal human ...
Tumor cells, however are highly abnormal, and many display unusual antigens. Some such tumor antigens are inappropriate for the ... Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies ... Humanised antibodies bind antigen much more weakly than the parent murine monoclonal antibody, with reported decreases in ... Increases in antibody-antigen binding strength have been achieved by introducing mutations into the complementarity determining ...
Neoplasms have no glandular differentiation (thus not resembling normal prostate tissue at all). It is composed of sheets ( ... are of Gleason scores 5-7 and are detected due to biopsy after abnormal digital rectal exam or prostate specific antigen ... If the neoplasm has only one pattern, the grade of that pattern is doubled to obtain the score. For example, if a tumor is ... Tumors with Gleason scores 8-10 tend to be advanced neoplasms that are unlikely to be cured. Although some evidence suggests ...
List of specialized glands within the human integumentary system List of target antigens in pemphigoid List of target antigens ... associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms ... of genes mutated in cutaneous conditions List of genes mutated in pigmented cutaneous lesions List of human leukocyte antigen ...
Balzar M, Winter MJ, de Boer CJ, Litvinov SV (October 1999). "The biology of the 17-1A antigen (Ep-CAM)". Journal of Molecular ... Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for ... Münz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (July 2004). "The carcinoma-associated antigen EpCAM upregulates c-myc ... Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (April 1994). "Ep-CAM: a human epithelial antigen is a homophilic ...
Typically, markers expressed in LCLC-RP include those seen in "generic" NSCLC's, such as epithelial membrane antigen (EMA, 61 ... They also more frequently express "non-carcinomatous" markers typically associated with "dedifferentiated" neoplasms. ... rhabdoid neoplasms (i.e. those that do not contain cells containing other histological variants) Lung cancers are now ... a rare neoplasm arising from transformed skeletal muscle. Despite their microscopic similarities, LCLC-RP is not associated ...
... lymphoid neoplasms, or features of both types of neoplasms. Most commonly, the present with features of myeloid neoplasms with ... It mediates at least in part the cell proliferating signaling stimulated by PDGF receptors as well as by antigen receptors on T ... Like the latter neoplasm, hematologic neoplasms cause by ETV6-JAK2 and BCR-JAK2 are aggressive and progress rapidly. Too few ... The FLT3 gene codes for the cluster of differentiation antigen 135 (i.e. CD135) protein or FLT3 protein. This protein is a ...
Neoplasms of the endolymphatic sac are very rare tumors. This article incorporates text in the public domain from page 1052 of ... Antigen diffusion from the perilymphatic space of the cochlea. Laryngoscope 1995; 105:623-628 Rask-Andersen H, Danckwardt- ...
Hemangiopericytoma is a rare vascular neoplasm, or abnormal growth, that may either be benign or malignant. In its malignant ... During the early proliferative phase (0-12 months) the tumors express proliferating cell nuclear antigen (pericytesna), ...
... system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in ... associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms ... cutaneous lesions List of histologic stains that aid in diagnosis of cutaneous conditions List of human leukocyte antigen ...
... but calreticulin is not a Ro/SS-A antigen. Earlier papers referred to calreticulin as an Ro/SS-A antigen, but this was later ... which makes CALR mutations the second most common in myeloproliferative neoplasms. All mutations (insertions or deletions) ... This association prepares the MHC class I for binding an antigen for presentation on the cell surface. Calreticulin is also ... "A human Ro/SS-A autoantigen is the homologue of calreticulin and is highly homologous with onchocercal RAL-1 antigen and an ...
A B cell is activated by its first encounter with an antigen (its "cognate antigen") that binds to its receptor, resulting in ... B cell receptor signalling is currently a therapeutic target in various lymphoid neoplasms. It has been shown that BCR ... On the other hand, pulling forces delinks the antigen from the BCR, thus testing the quality of antigen binding. The receptor's ... Each B cell, produced in the bone marrow, is highly specific to an antigen. The BCR can be found in a number of identical ...
... system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in ... neoplasms, and cysts are skin lesions that develop from the epidermal layer of the skin. Aberrant basal cell carcinoma ... an overview with emphasis on the myeloid neoplasms". Chem. Biol. Interact. 184 (1-2): 16-20. doi:10.1016/j.cbi.2009.10.009. ... neoplasms invading or aberrantly present in the dermis. Acquired progressive lymphangioma (benign lymphangioendothelioma) Acral ...
... system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in ... associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms ... cutaneous lesions List of histologic stains that aid in diagnosis of cutaneous conditions List of human leukocyte antigen ...
Every helper T-cell is specific to one particular antigen. Only professional antigen-presenting cells (APCs: macrophages, B ... Blastic plasmacytoid dendritic cell neoplasm is a rare type of myeloid cancer in which malignant pDCs infiltrate the skin, bone ... Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They ... Here they act as antigen-presenting cells: they activate helper T-cells and killer T-cells as well as B-cells by presenting ...
The hairy cells are larger than normal and positive for CD19, CD20, CD22, CD11c, CD25, CD103, and FMC7 antigens. (CD103, CD22, ... and most kinds of blood neoplasms, including hypoplastic myelodysplastic syndrome, atypical chronic lymphocytic leukemia, B- ... usually showing a common Human Leukocyte Antigen (HLA) type. The Hairy Cell Leukemia Consortium was founded in 2008 to address ... data from chronic lymphocytic leukemia and non-Hodgkin lymphoma to conclude that HCL and other rare B-cell neoplasms may share ...
The critical diagnosis of this neoplasm is often difficult because of its similarity with other primary or secondary papillary ... epithelial membrane antigen) → - GFAP (glial fibrillary acidic protein) → + Synaptophysin → - Chromogranin → - NSE (neuron- ... is a recently described neoplasm that has been formally recognized in the 2007 World Health Organization (WHO) "Classification ...
ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... Bone marrow tumour cells express the following antigen targets CD20 (98.3%), CD22 (88.3%), CD40 (83.3%), CD52 (77.4%), IgM ( ... Hematologic malignant neoplasms, Lymphoma, Rare cancers, Vascular-related cutaneous conditions). ... "Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations". ...
Prostate-specific membrane antigen (PSMA) stimulates cancer development by increasing folate levels, helping the cancer cells ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ (February 2010). "Expression of prostate-specific membrane antigen (PSMA), ... Cabarkapa S, Perera M, McGrath S, Lawrentschuk N (December 2016). "Prostate cancer screening with prostate-specific antigen: A ...
CD4 antigen - CD45 antigen - CD95 antigen - CDC28 protein kinase - cell - cell adhesion molecule - cell biology - cell cycle ... neoplasm protein - Nernst equation - nerve - nerve growth factor - nerve growth factor receptor - nerve tissue protein - nerve ... T-cell antigen receptors - tachykinin - tachykinin receptor - talin protein - tandem repeat sequence - taste bud - TATA box - ... carcinoembryonic antigen - carrier - carrier protein - CAS registry number - casein - catabolism - catalyst - catalytic domain ...
Valent investigates the phenotype of these cells in various hematologic neoplasms and develops concepts predicting the step- ... "Variable expression of activation-linked surface antigens on human mast cells in health and disease.". Immunol Rev. 179 (179): ...
This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... or one of the various tests for hepatitis C antigen. Extracavitary PEL is diagnosed based on findings that their mass lesions ... List of hematologic conditions Chen BJ, Chuang SS (March 2020). "Lymphoid Neoplasms With Plasmablastic Differentiation: A ... "Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the ...
Reth M (1992). "Antigen receptors on B lymphocytes". Annual Review of Immunology. 10 (1): 97-121. doi:10.1146/annurev.iy. ... and is also present in virtually all B-cell neoplasms, including B-cell lymphomas, plasmacytomas, and myelomas. It is also ... Engels N, Wollscheid B, Wienands J (Jul 2001). "Association of SLP-65/BLNK with the B cell antigen receptor through a non-ITAM ... Brown VK, Ogle EW, Burkhardt AL, Rowley RB, Bolen JB, Justement LB (Jun 1994). "Multiple components of the B cell antigen ...
CD10+ differentiates mucinous cystic neoplasms (CD10+/CK20+) from intraductal papillary mucinous neoplasm of branch duct type ( ... It is also a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute ... Murali R, Delprado W (2005). "CD10 immunohistochemical staining in urothelial neoplasms". Am. J. Clin. Pathol. 124 (3): 371-9. ... and common acute lymphoblastic leukemia antigen (CALLA) is an enzyme that in humans is encoded by the MME gene. Neprilysin is a ...
Proliferating cell nuclear antigen (PCNA) is a protein involved in DNA synthesis. Under normal physiological conditions PCNA is ... Kales SC, Ryan PE, Nau MM, Lipkowitz S (June 2010). "Cbl and human myeloid neoplasms: the Cbl oncogene comes of age". Cancer ... Ishikura S, Weissman AM, Bonifacino JS (July 2010). "Serine residues in the cytosolic tail of the T-cell antigen receptor alpha ... The ubiquitination system functions in a wide variety of cellular processes, including: Antigen processing Apoptosis Biogenesis ...
2006). "Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody ... IGHV is the immunoglobulin heavy chain variable region genes; in B-cell neoplasms like chronic lymphocytic leukemia, mutations ...
Cao JX, Gao WJ, You J, Wu LH, Liu JL, Wang ZX (July 2019). "The efficacy of anti-CD19 chimeric antigen receptor T cells for B- ... Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the ... Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (August 2011). "T cells with chimeric antigen receptors have ... Porter DL, Levine BL, Kalos M, Bagg A, June CH (August 2011). "Chimeric antigen receptor-modified T cells in chronic lymphoid ...
... the nonspecific cross-reacting antigen of carcinoembryonic antigen". Cancer Res. 57 (24): 5460-5464. PMID 9407950. Kawaharata H ... In contrast to most other cancers, adrenocortical neoplasms appear to have decreased expression of H19. To determine a possible ... p95, or NCA-90, is related to carcinoembryonic antigens, which have been found to reduce drug toxicity by Kawaharata et al. NCI ... Hinoda Y, Itoh F, Endo T, Oikawa S, Nakazato H, Imai K (July 1997). "Decreased sensitivity of carcinoembryonic antigen cDNA- ...
As in other tissues, Langerhans cells in the epithelium take up antigens from the microbes, and present them to the immune ... induced Genetic/developmental disorders Specific infections Inflammatory and immune conditions Reactive processes Neoplasms ...
Another important surface antigen is CD319 (SLAMF7). This antigen is expressed at high levels on normal human plasma cells. It ... and plasma cell leukemia are malignant neoplasms ("cancer") of the plasma cells. Multiple myeloma is frequently identified ... After leaving the bone marrow, the B cell acts as an antigen-presenting cell (APC) and internalizes offending antigens, which ... The absence of antigens and the depletion of B cells does not appear to have an effect on the production of high-affinity ...
Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors ... May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ... TdT is a protein expressed early in the development of pre-T and pre-B cells, whereas CALLA is an antigen found in 80% of ALL ... The process as a whole result in an effector cell, typically a T-cell, that can recognize a tumor cell antigen in a manner that ...
2009). "Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis". Int J ... been identified as an intracellular target of the natural product sanglifehrin A This gene is up-regulated in some neoplasms, ...
Tissue antigens. 70(2):105-109, 2007 Cruz AAV. Orbital inflammation and infection versus neoplasia. In: Karcioglu ZA, ed. ... Its diagnosis is of exclusion once neoplasm, primary infection and systemic disorders have been ruled out. Once diagnosed, it ... However, one study by Mottow-Lippe, Jakobiec, and Smith suggests that the release of circulating antigens caused by local ... Its former name, orbital pseudotumor, is derived due to resemblance to a neoplasm. However, histologically it is characterized ...
CD140B+Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Portal: Biology (Articles with short ... This continuous signaling, it is presumed, leads to the development of myeloid and/or lymphoid neoplasms that commonly include ... PDGFRB-ETV6 fusion protein-induced neoplasms often present with features that would classify them as Chronic myelomonocytic ... These patients, unlike many patients with similarly appearing neoplasms, respond well to the tyrosine kinase inhibitor, ...
B-cell-associated antigens such as CD19, CD20, CD22, and CD79a are usually expressed. In contrast to small lymphocytic lymphoma ... ISBN 0-7817-5007-5. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ...
... which is linked to increased resistance to chemotherapy and radiation therapy It is a specific antigen on multiple myeloma ... a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms". American Journal of Clinical ...
Direct measurement of antigens, such as hCG, was made possible after the invention of the radioimmunoassay in 1959. ... and gestational trophoblastic neoplasms). bacterial contamination and blood in urine Spurious evaporation lines may appear on ...
Baranov E, Hornick JL (March 2020). "Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck ... analyses indicate that the tumor cells in GCF express CD34 and vimentin proteins but not epithelial membrane antigen (also ...
... which is a glycoprotein that serves as a ligand for macrophage-1 antigen (Mac-1) and lymphocyte function-associated antigen 1 ( ... Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal ... which is a glycoprotein that serves as a ligand for macrophage-1 antigen (Mac-1) and lymphocyte function-associated antigen 1 ( ... July 2008). "Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of ...
A phase I clinical trial is recruiting individuals to study the side effects and efficacy of CD19/CD22 chimeric antigen ... An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation". The ... "Phase I CD19/CD22 Chimeric Antigen Receptor(CAR) T-Cells in Adults With Recurrent/Refractory B Cell Malignancies - Full Text ... Epstein-Barr virus nuclear antigen 2 (EBNA-2) (a protein which stimulates infected cells to make >300 gene products some of ...
Adoptive immunotherapy seeks to expand a population of the body's T-cells that will recognize a specific tumor antigen. T-cells ... a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study ... They can also include the administration of laboratory-produced antibodies specific to tumor antigens to create or boost an ... Vaccines can deliver various tumor-associated factors (tumor antigens) to the immune system, resulting in a natural antibody ...
CK19, Cytokeratin 19, K19) Kit L-selectin (CD62L) Lamin A/C Lewis X antigen (Le(X)) LeX Lgr5 Lrp4 MCM2 MCSP Metallothionein (MT ... Misago N, Narisawa Y (September 2006). "Cytokeratin 15 expression in neoplasms with sebaceous differentiation". Journal of ... May 2006). "Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell ... Muramatsu T, Muramatsu H (2004). "Carbohydrate antigens expressed on stem cells and early embryonic cells". Glycoconjugate ...
Carcinoembryonic Antigen, and Amylase in Intraductal Papillary Mucinous Neoplasm, Pancreas, vol. 45, no. 6, pp. 870-875. https ... Carcinoembryonic Antigen, and Amylase in Intraductal Papillary Mucinous Neoplasm. Together they form a unique fingerprint. ... Objectives The aim of this study was to determine the accuracy of cytology, carcinoembryonic antigen (CEA), and amylase levels ... Carcinoembryonic antigen modestly differentiated between mucinous and nonmucinous lesions. Amylase did not distinguish IPMNs ...
Fetal antigens and cancer. Series: Ciba Foundation symposium ; 96Material type: Text; Format: print Publication details: London ...
Intracytoplasmic antigen study by flow cytometry in hematolymphoid neoplasm.. 作者: Gujral, Sumeet. Tembhare, Prashant. Badrinath ... Intracytoplasmic antigen study by flow cytometry in hematolymphoid neoplasm. Indian Journal of Pathology & Microbiology. 2009 ... Detection of intracellular antigens by flow cytometry (FCM) requires effective fixation and permeabilization of the cell ... It has a non-debatable contribution to the diagnosis of hematolymphoid neoplasm as well as in minimal residual disease. ...
To activate these CD8(+) T cells, antigen-presenting cells (APCs) must initially acquire tumor cell-associated antigens. The ... major source of tumor antigens is dead tumor cells, but … ... Antigens, Neoplasm / immunology * CD11c Antigen / biosynthesis ... To activate these CD8(+) T cells, antigen-presenting cells (APCs) must initially acquire tumor cell-associated antigens. The ... However, tumor antigen-specific CD8(+) T cell activation and subsequent antitumor immunity are severely impaired in mice ...
A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated ... ALTHOUGH CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS. as a treatment for B-cell neoplasms have shown some promising results in ... Ibrutinib Prevents Cytokine-Release Syndrome After CAR T-Cell Therapy for B-Cell Neoplasms Jan 18, 2017. Christina Mattina ... "Cytokine-release syndrome is a serious adverse event of anti-CD19 chimeric antigen receptor T-cell (CART19) therapy and could ...
CA-125 Antigen / metabolism* * Carcinoma, Ovarian Epithelial * Female * Humans * Neoplasms, Glandular and Epithelial / ...
Carcinoembryonic antigen. Most epithelial neoplasms of the ovary also express carcinoembryonic antigen (CEA). The neoplasms ... Squamous cell carcinoma antigen. The squamous cell carcinoma antigen level can be increased in patients with epidermoid ... Cancer antigen 125. National Comprehensive Cancer Network (NCCN) guidelines recommend that if the cancer antigen 125 (CA-125) ... L1 (CAM) (CD171) in ovarian serous neoplasms. Eur J Gynaecol Oncol. 2008. 29(1):26-30. [QxMD MEDLINE Link]. ...
Prostate-Specific Antigen /blood; Prostatic Neoplasms /drug therapy /prevention & control; Randomized Controlled Trials as ... Change in prostrate-specific antigen levels: One RCT (n=54) found a significantly lower mean for prostrate-specific antigen in ... Prostrate-specific antigen levels were extracted using the parameters of the published papers, which were chiefly means with ... For the non-RCT (n=66) there was a significant reduction in mean prostrate-specific antigen after treatment from 10.9ngmL-1 (SD ...
... persistently transduced with a Preferentially Expressed Antigen in Melanoma (PRAME)-specific human leukocyte antigen (HLA)-A*02 ... TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms. The safety and scientific validity of this study is ... Human leukocyte antigen (HLA):. *Phase I and Phase II (treatment group): Subjects positive for HLA-A*02:01 according to ... The Phase I dose escalation part will establish the MTD/RP2D in subjects with high risk myeloid and lymphoid neoplasms, a total ...
Choroid plexus neoplasms are rare, intraventricular, primary central nervous system (CNS) tumors derived from choroid plexus ... 22, 37, 38, 39, 40] Ethidium monoazide (EMA) is usually negative, as is carcinoembryonic antigen (CEA). [37, 38] ... encoded search term (Pathology of Choroid Plexus Neoplasms) and Pathology of Choroid Plexus Neoplasms What to Read Next on ... Pathology of Choroid Plexus Neoplasms. Updated: Jan 10, 2018 * Author: Christine Fuller, MD; Chief Editor: Adekunle M Adesina, ...
Neoplasm Antigens 6% * Ovary 5% * Peptides 62% * polypeptide C 28% * T-Lymphocyte Epitopes 7% ...
prostate-specific antigen, biopsy, prostate, prostatic neoplasms, diagnosis. in Journal of Urology. volume. 184. issue. 3. ... We evaluated whether prostate specific antigen velocity improved predictive accuracy beyond that of prostate specific antigen ... We evaluated whether prostate specific antigen velocity improved predictive accuracy beyond that of prostate specific antigen ... We evaluated whether prostate specific antigen velocity improved predictive accuracy beyond that of prostate specific antigen ...
Use ONLY diagnosis code Z12.5: Screening for malignant neoplasms of prostate. No other diagnosis code is covered by Medicare ... Prostate-specific antigen testing, Medicare. Applies to:. Medicare Advantage plans. Definition. A prostate-specific antigen ( ... Bill 84153: Prostate-specific antigen (PSA), total *Use the diagnosis code for the condition being treated. See Section 190.31 ... Bill G0103: Prostate cancer screening, prostate-specific antigen (PSA), total * ...
... specific antigen (PSA) plays an important role in the diagnosis and management of prostate cancer. The utility of PSA has been ... Prostatic‐specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer 1981; 48. :1229-32.. ... specific antigen, prostate‐specific antigen nadir, time to prostate‐specific antigen nadir, prostatic‐specific antigen ... 2] later characterized prostate‐specific antigen (PSA) as a potential immunohistologic marker for prostatic neoplasms. The ...
blackberries, etc ; DNA demethylation; DNA methylation; alkaline phosphatase; antigens; cell differentiation; colorectal ... neoplasms; dose response; epigenetics; epithelial cells; genes; humans; nutrition; Show all 13 Subjects. Abstract:. ... Fruit- ...
Prostate-Specific Antigen [‎2]‎. Prostatic Hyperplasia [‎2]‎. Prostatic Neoplasms [‎14]‎. Prostheses and Implants [‎15]‎. ...
Antigens, Neoplasm [D23.050.285]. *Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]. *Lewis X Antigen [D23.050. ... A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the ... "Lewis X Antigen" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Lewis X Antigen" by people in this website by year, and ...
Leukocyte common antigen--a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections ... Safai B, Diaz B, Schwartz J. Malignant neoplasms associated with human immunodeficiency virus infection. CA Cancer J Clin. 1992 ...
keywords = "Prostate, Prostate-specific antigen, Prostatic neoplasms, ROC curve",. author = "Brawer, {Michael K.} and Cheli, { ... Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific ... Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific ... Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific ...
Neoplasm Antigens Medicine & Life Sciences 74% * DNA Tumor Viruses Medicine & Life Sciences 56% ... p300 Family members associate with the carboxyl terminus of simian virus 40 large tumor antigen. In: Journal of virology. 1997 ... Like p300, p400 is a phosphoprotein that binds to the simian virus 40 large tumor antigen (T). In anti-T coimmunoprecipitation ... Like p300, p400 is a phosphoprotein that binds to the simian virus 40 large tumor antigen (T). In anti-T coimmunoprecipitation ...
Moreover, viral antigen was detected in spindle cells. However, it was unclear that infection by CbGHV1 was sufficient to ... an endothelial neoplasm of the dermis, oral cavity and intestinal organs. The tumors are highly vascularized and characterized ... which harbored viral antigen. Although the disease symptoms did not fully match those of Kaposi sarcoma in humans (3,4), in ... serum from the animal was reactive against KSHV antigen in an ELISA (Figure 2, panel B) and an immunofluorescence-based assay ( ...
Neoplasm Antigens Medicine & Life Sciences 83% * amidase Medicine & Life Sciences 78% * Antibodies Medicine & Life Sciences 69% ... L2A5 antibody or functional fragment thereof against tumour antigens. Videira, P. A. Q., Novo, C. M. M., Loureiro, L. R. R., ... L2A5 Antibody or functional fragment thereof against tumour antigens. Videira, P. A. Q., Novo, C. M. M., Loureiro, L. R. R., ... L2A5 ANTIBODY OR FUNCTIONAL FRAGMENT THEREOF AGAINST TUMOUR ANTIGENS. Videira, P. A. Q., Novo, C. M. M., Loureiro, L. R. R., ...
PSA (prostate-specific antigen) testing detected many more cancers-which led to many more biopsies and treatments. However, the ... Not long ago, prostate cancer was commonly detected with a digital rectal examination, which revealed palpable neoplasms. ...
PDI antigen determined in releasates and lysates using PDI ELISA (n = 3; **, P = 0.002). E, Comparison of PDI antigen in ... Myeloproliferative neoplasms (MPN) are disorders of the bone marrow characterized by excess clonal hematopoiesis resulting in ... PDI antigen determined in releasates and lysates using PDI ELISA (n = 3; **, P = 0.002). E, Comparison of PDI antigen in ... Plasma PDI antigen was measured for all study subjects at time of study enrollment. Plasma PDI antigen was normally distributed ...
We studied the usefulness of transrectal sonography, prostate- specific antigen levels, and prostate-specific antigen density ... Neoplasm Medicine and Dentistry 31% * Carcinoma Medicine and Dentistry 12% * Digital Rectal Examination Medicine and Dentistry ... We studied the usefulness of transrectal sonography, prostate- specific antigen levels, and prostate-specific antigen density ... We studied the usefulness of transrectal sonography, prostate- specific antigen levels, and prostate-specific antigen density ...
Immunohistochemical expression of prostate specific antigen in normal breast tissue and breast neoplasms. Mod Pathol 16(1):29A ...
Webcast, Evidence-Based Medicine, CA-125 Antigen, Ovarian Neoplasms/diagnosis, Primary Health Care ...
Differentiation Antigens Medicine & Life Sciences 68% * Neoplasm Antigens Medicine & Life Sciences 65% ... Study objective: The aim of our study was to assess the clinical value of CYFRA 21-1 tumor marker and carcinoembryonic antigen ... The aim of our study was to assess the clinical value of CYFRA 21-1 tumor marker and carcinoembryonic antigen (CEA) as ... The aim of our study was to assess the clinical value of CYFRA 21-1 tumor marker and carcinoembryonic antigen (CEA) as ...
Receptors, Antigen, T-Cell [‎1]‎. Receptors, Fc [‎2]‎. Receptors, Virus [‎1]‎. Rectal Neoplasms [‎1]‎. ...
  • BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs). (
  • These therapies include chimeric antigen receptor T cells, antibody-drug conjugate, and Bi-specific antibodies. (
  • Leukocyte common antigen-a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. (
  • They can also exhibit antibodies to antigens associated with pemphigus vulgaris (desmoglein 3, 130-kd) and pemphigus foliaceus (desmoglein 1, 160-kd), as well as several others, including epiplakin. (
  • In one report, a subset of patients with limbic encephalitis associated with a systemic neoplasm previously attributed to antibodies against voltage gated potassium channel antibodies actually recognize LGI1 protein complex epitopes and do not represent a channelopathy. (
  • Using this staining technique, fluorescent dye is attached to the known antibodies that correspond to the suspected antigen, in this case, the leukemia cells. (
  • These antibodies will in turn attach to the antigen molecules on the cell surfaces, and if present, will fluoresce when viewed with a fluorescent light. (
  • Purpose: Determining serum total prostate specific antigen (PSA) has proved to be a valuable diagnostic aid for detecting prostatic carcinoma, although the lack of specificity has limited its usefulness. (
  • We studied the usefulness of transrectal sonography, prostate- specific antigen levels, and prostate-specific antigen density as indications for directed and random biopsies of the prostate in patients with possible prostatic cancer. (
  • There are scant data available on the relationship between smoking and total prostate specific antigen, free prostate specific antigen and percent-free prostate specific antigen. (
  • Multivariate linear regression analysis showed that total prostate specific antigen was 7.9% and 12.2% lower among current and former smokers, respectively, than among never smokers. (
  • High body mass index and diabetes were also statistically significantly associated with a lower total prostate specific antigen. (
  • Our finding that smoking is inversely associated with total prostate specific antigen may have potential implications for the interpretation of prostate specific antigen levels in men who are current or former smokers. (
  • September 19, 2022) A Case Report of Pseudomyxoma Peritonei Arising From Primary Mucinous Ovarian Neoplasms. (
  • We report two rare cases of PMP originating from mucinous primary ovarian neoplasms. (
  • Researchers at the National Cancer Institute's Experimental Transplantation and Immunology Branch (NCI ETIB) developed a T Cell receptor that specifically targets the Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) 52-60 epitope that is highly expressed by several common and aggressive epithelial tumor types. (
  • Cytokine-release syndrome is a serious adverse event of anti-CD19 chimeric antigen receptor T-cell (CART19) therapy and could potentially limit its widespread clinical use," explained lead study author Marco Ruella, MD, clinical instructor at the Perelman School of Medicine Center for Cellular Immunotherapies at the University of Pennsylvania. (
  • This is a multicentre, non-randomized, open-label, Phase I/II clinical trial of MDG1011, an investigational medicinal product (IMP), consisting of patient-derived autologous T cells, persistently transduced with a Preferentially Expressed Antigen in Melanoma (PRAME)-specific human leukocyte antigen (HLA)-A*02:01-restricted T cell receptor (TCR). (
  • PRAME (PReferentially expressed Antigen in MElanoma) is a tumor biomarker expressed in most cutaneous and ocular melanomas as well as various other malignant neoplasms. (
  • Objectives The aim of this study was to determine the accuracy of cytology, carcinoembryonic antigen (CEA), and amylase levels in the preoperative diagnosis of intraductal papillary mucinous neoplasms (IPMNs). (
  • Carcinoembryonic antigen was a poor predictor of neoplasia in IPMNs (AUC = 0.55). (
  • Carcinoembryonic antigen modestly differentiated between mucinous and nonmucinous lesions. (
  • Study objective: The aim of our study was to assess the clinical value of CYFRA 21-1 tumor marker and carcinoembryonic antigen (CEA) as diagnostic tools that are complementary to cytology in the diagnosis of malignant mesotheliomas. (
  • The presence of a primary signet ring cell carcinoma of the prostate was best confirmed by negative findings on gastrointestinal work-up, a positive stain for prostate-specific acid phosphatase, and negative carcinoembryonic antigen test results. (
  • It has a non-debatable contribution to the diagnosis of hematolymphoid neoplasm as well as in minimal residual disease. (
  • S erum carbohydrate antigen 19-9 (CA19-9) is mainly used for the diagnosis and prognostic assessment of pancreatobiliary neoplasms. (
  • Killer cell immunoglobulin-like receptors (KIR) are involved in the regulation of NK cell activation through recognition of their human leukocyte antigen (HLA) class I ligands. (
  • To investigate whether killer cell immunoglobulin-like receptor (KIR) and human leukocyte antigen (HLA) genetic background could influence the onset age of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) infection, one hundred and seventy-one males with HBV-related HCC were enrolled. (
  • However, the small increase in risk associated with high prostate specific antigen velocity (from 1.7% to 2.8% as velocity increased from 0 to 1 ng/ml per year) had questionable clinical relevance. (
  • Conclusions: The factors that are invariably used to predict overall biochemical recurrence following radical prostatectomy, including high prostate specific antigen, high grade and adverse pathological findings, also predict aggressive recurrence. (
  • Purpose: Short prostate specific antigen doubling time following recurrence after radical prostatectomy portends a poor prognosis in men with prostate cancer. (
  • We used logistic regression analysis to determine the independent factors associated with a short prostate specific antigen doubling time of less than 9 months vs a longer doubling time of 9 months or greater, or no recurrence. (
  • Based on these risk factors we developed a table to estimate the risk of recurrence with a prostate specific antigen doubling time of less than 9 months. (
  • What are the Factors Associated With Short Prostate Specific Antigen Doubling Time After Radical Prostatectomy? (
  • We determined which demographic and clinicopathological variables were predictive of a short prostate specific antigen doubling time in a cohort of men with clinically localized prostate cancer treated with radical prostatectomy. (
  • Dive into the research topics of 'What are the Factors Associated With Short Prostate Specific Antigen Doubling Time After Radical Prostatectomy? (
  • A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated longer overall survival and reduced cytokine production than the mice not treated with ibrutinib. (
  • However, although the blood-brain barrier and the claimed immunological privilege of the brain are not necessarily obstacles to effective brain immunotherapy, these strategies are currently limited by the paucity of cloned NS target antigens and the fact that our understanding of anti-tumour immune responses in the NS is frequently extrapolated from other tissues having little in common with it [ 7 , 8 ]. (
  • Pseudomyxoma peritonei (PMP) is a rare disease arising from primary mucinous tumors, which are usually appendiceal mucinous epithelial neoplasms and rarely mucinous ovarian tumors [1] . (
  • Solid pseudopapillary neoplasm/tumor, also known as papillary epithelial neoplasm, Hamoudi or Frantz tumor, is a low-grade or borderline epithelial pancreatic malignancy and has been reported in 0.9-2.7% of all neoplasms of the organ [1, 2]. (
  • Thymomas, tumors that arise from epithelial cells of the thymus gland, are the most common neoplasms of the anterior mediastinum, with an incidence rate of approximately 2.5 per million/year. (
  • BACKGROUND: The Cancer/Testis Antigens (CTAs) are a heterogeneous group of proteins whose expression is typically restricted to the testis. (
  • However, tumor antigen-specific CD8(+) T cell activation and subsequent antitumor immunity are severely impaired in mice depleted with CD169(+) macrophages. (
  • Thus, we have identified CD169(+) macrophages as lymph node-resident APCs dominating early activation of tumor antigen-specific CD8(+) T cells. (
  • Like p300, p400 is a phosphoprotein that binds to the simian virus 40 large tumor antigen (T). In anti-T coimmunoprecipitation experiments, staggered deletions spanning the amino-terminal 250 amino acids of T did not abrogate T binding to either p400 or p300. (
  • Choroid plexus neoplasms are rare, intraventricular, primary central nervous system (CNS) tumors derived from choroid plexus epithelium that are seen predominantly in children. (
  • [ 2 , 3 ] In adults, they account for less than 1% of primary intracranial neoplasms, whereas choroid plexus tumors represent up to 5% of pediatric brain tumors, and up to 20% of those arising in children aged 1 year and younger. (
  • The animal had multiple oral tumors characterized by proliferation of latent nuclear antigen 1-positive spindle cells and was not co-infected with immunosuppressive simian viruses, suggesting that it had Kaposi sarcoma caused by this novel rhadinovirus. (
  • The tumors are highly vascularized and characterized by proliferation of spindle cells that contain KSHV DNA and antigen ( 2 , 3 ). (
  • Cytotoxic T Lymphocyte Antigen 4 (CTLA-4 or CD152) exerts inhibitory activity on T cells, and since its oncogenic role in the progression of different types of tumors, it has emerged as a potential therapeutic target in cancer patients. (
  • Immunohistochemical and ultrastructural examination revealed that the transgenic brain tumors were undifferentiated and lacked all antigens associated with normal murine neuronal, glial, and ependymal cells. (
  • By immunoprecipitation, target antigens were identified from skin extracts with molecular weights of 250, 230, 210, and 190 kd. (
  • Immunohistochemical staining of melanoma tissues from which vaccine was produced revealed high expression of both HLA class I and melanoma antigens in seven of eight clinical responders (two with CR, three with SD, and the three with long-term disease-free survival) and in four of 12 nonresponders. (
  • Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spongy tissue of the bone marrow. (
  • Thromboembolic events (TE) are the most common complications of myeloproliferative neoplasms (MPN). (
  • Pseudomyxoma peritonei (PMP) is a rare manifestation of primary mucinous neoplasms. (
  • The hand-assisted laparoscopic approach to resection of pancreatic mucinous cystic neoplasms: An underused technique? (
  • Histopathology may be insufficient, requiring positive immunohistochemistry for S-100 protein and other antigens of melanocytic differentiation. (
  • The first heritable model of retinoblastoma was established by retina-specific expression of simian virus 40 T-antigen (SV40 T-ag) in transgenic mice. (
  • It has low serum prostate specific antigen (PSA) level disproportionately to the tumor burden. (
  • cancer is combined digital rectal exam and Blood samples were taken and 1 mL of determination of serum prostate specific centrifuged serum was used for the PSA antigen (PSA) level. (
  • Purpose: Prostate specific antigen velocity has been proposed as a marker to aid in prostate cancer detection. (
  • We found little evidence to support prostate specific antigen velocity to aid in decisions about repeat biopsy for prostate cancer. (
  • A prostate-specific antigen (PSA) blood test screens for prostate cancer by measuring the amount of PSA, a protein produced by tissue in the prostate. (
  • Not long ago, prostate cancer was commonly detected with a digital rectal examination, which revealed palpable neoplasms. (
  • Prostate magnetic resonance imaging (MRI) is increasingly used prior to biopsy in response to the overdiagnosis and overtreatment of prostate cancer (CaP) associated with prostate-specific antigen (PSA) based screening. (
  • The natural ageing of the population as well as the continued and widespread use of diagnostic tests such as prostate specific antigen (PSA), has led to an increase in the numbers of men diagnosed with localised prostate cancer. (
  • It has recently been included in the cancer/testis (CT) antigen family, and shown to be expressed in multiple myeloma and ovarian cancer. (
  • PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis. (
  • Due to its high levels of expression in the testis and to its specific relationship to cancer, PLU-1 has been proposed to belong to the family of testis-cancer antigens. (
  • Combination of analysis of fluorescence labeling and light scatter properties of cells allows rapid and better determination of target cell antigens. (
  • To activate these CD8(+) T cells, antigen-presenting cells (APCs) must initially acquire tumor cell-associated antigens. (
  • The major source of tumor antigens is dead tumor cells, but little is known about how APCs in draining lymph nodes acquire and crosspresent these antigens. (
  • Here we show that CD169(+) macrophages phagocytose dead tumor cells transported via lymphatic flow and subsequently crosspresent tumor antigens to CD8(+) T cells. (
  • Neither migratory dendritic cells (DCs) nor lymph node-resident conventional DCs are essential for the crosspresentation of tumor antigens. (
  • B-Cell maturation antigen (BCMA) is a cell surface protein that is expressed on the malignant plasma cells. (
  • Also, these antigens are hardly detected in the malignant plasma cells thus suggesting BCMA to be a standard choice over the other targeting antigens. (
  • CD45 recognizes an antigen found on lymphoid cells. (
  • Antigen-specific antimelanoma T-cell response was assessed by enzyme-linked immunospot (ELISPOT) assay on peripheral blood mononuclear cells (PBMCs) obtained before and after vaccination. (
  • Cells labeled with MagDots targeting specific antigens will be both fluorescent and magnetic. (
  • The CD3 complex, which is assembled from combinations of CD3γ, δ, ε, η, and ζ subunits, associates non-covalently with the TCR and is involved in transducing antigen recognition signals into the cytoplasm of T cells and in regulating the cell surface expression of the TCR. (
  • Fetal antigens and cancer. (
  • The primary outcome was disease progression of prostrate cancer measured by change in prostrate-specific antigen level. (
  • There was some evidence that prostate specific antigen velocity improved AUC compared to prostate specific antigen for high grade cancer. (
  • Thirty-nine (97%) of 40 patients with cancer had either sonographic findings suggestive of tumor or increased prostate-specific antigen density, and one (3%) had no evidence of tumor on sonography and a normal prostate-specific antigen density. (
  • Both of the patients underwent evaluation comprising cancer antigen-125 (CA-125) levels, ultrasound (US) examination of the abdomen and the pelvis, tumor markers, cytological evaluation, and contrast-enhanced computed tomography (CECT) of the pelvis and abdomen. (
  • The expression level of the tumor marker cancer antigen-125 (CA-125) was 61.2 U/ml (normal range: 0-35 units/mL). (
  • A few notes on each cancer site and its subgroups staining techniques (e.g., glandular and diffuse neoplasms of are included in this chapter. (
  • The sample second after lung cancer as the most preva- size was calculated with level of 0.05 and lent neoplasm in men. (
  • The major neoplasm worldwide is oral cancer. (
  • Scientists at the National Cancer Institute (NCI) developed a potent chimeric antigen receptor (CAR) targeting glypican-3 (GPC3). (
  • we calculated a sensitivity of 72% and a specificity of 56% for the combination of sonographic findings suggestive of tumor and increased levels of prostate-specific antigen. (
  • The Phase I dose escalation part will establish the MTD/RP2D in subjects with high risk myeloid and lymphoid neoplasms, a total of 3 disease entities. (
  • A mutation in the PTCH gene, involved in Gorlin-Goltz syndrome, could be associated with the pathogenesis of this neoplasm. (
  • Lewis X Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (
  • Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. (
  • The variables analyzed were patient age, race, logarithmically transformed preoperative prostate specific antigen, body mass index, year of surgery, pathological Gleason sum, extraprostatic extension, surgical margin status and seminal vesicle invasion. (
  • The overall annual incidence of choroid plexus neoplasms for all ages is 0.3 cases per million. (
  • A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. (
  • CD45 belongs to a leukocyte common antigen (LCA antibody) family of glycoproteins with molecular weights of 180, 190, 205 and 220 kDa. (
  • Flow cytometric detection of intracellular antigens has become a standard method in establishing proper leukemic cell lineage affiliation. (
  • Regarding the detection of intracellular antigens, standardization of the procedure remains, however, a real challenge. (
  • Detection of intracellular antigens by flow cytometry (FCM) requires effective fixation and permeabilization of the cell membrane. (
  • The detection of HHV-1 antigen, chemicals and radiation, found to play important role in the development of oral cancers in Iraq. (
  • The third ventricle is the least common intraventricular location for choroid plexus neoplasms, irrespective of patient age. (
  • A total of 141 patients with increased levels of prostate-specific antigen or abnormal findings on digital rectal examination had transrectal sonography of the prostate and determination of prostate-specific antigen density. (
  • as a treatment for B-cell neoplasms have shown some promising results in clinical trials, their clinical use is limited, partially due to the risk of cytokine-release syndrome (CRS) occurring in response to the treatment. (
  • The distributions of total, free and percent free prostate specific antigen were estimated by sociodemographic and clinical characteristics. (
  • The clinical presentation is variable and nonspecific, easily confused with other fibrous neoplasms. (
  • The robust pipeline of therapies for the treatment of multiple myeloma is expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market. (
  • Key players operating in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc. (
  • A majority of T cell neoplasms also express CD3. (
  • Immunostaining for leukocyte common antigen using an Amplified avidin-biotin-peroxidase complex method and paraffin sections. (
  • Given the high prevalence of smoking and the frequency of prostate specific antigen screening, it is important to determine any association between smoking and prostate specific antigen values using nationally representative data. (
  • We evaluated whether prostate specific antigen velocity improved predictive accuracy beyond that of prostate specific antigen alone. (